

A45

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 934 931 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

11.08.1999 Bulletin 1999/32

(51) Int. Cl.⁶: C07D 209/34

(21) Application number: 99103667.4

(22) Date of filing: 05.06.1996

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

Designated Extension States:

AL LT LV SI

(30) Priority: 07.06.1995 US 485323

(62) Document number(s) of the earlier application(s) in

accordance with Art. 76 EPC:

96918093.4 / 0 769 947

(71) Applicant: Sugen, Inc.

Redwood City, CA 94063 (US)

(72) Inventors:

• Tang, Peng Cho

Moraga, CA 94556 (US)

• Sun, Li

Foster City, CA 94404 (US)

• McMahon, Gerald

Kenwood, CA 95452 (US)

(74) Representative:

Viering, Jentschura & Partner

Postfach 22 14 43



80504 München (DE)

Remarks:

This application was filed on 25 - 02 - 1999 as a
divisional application to the application mentioned
under INID code 62.

(54) 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators

(57) The present invention relates to compounds of the formulae



wherein

X is Br, Cl, F or I;

EP 0 934 931 A2

capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

EP 0 934 931 A2

Description

[0001] This application is a continuation-in-part of U.S. Patent Application Serial No. 08/485,323, filed June 7, 1995, which is hereby incorporated by reference in its entirety.

1. INTRODUCTION

[0002] The present invention relates to novel compounds capable of modulating, regulating and/or inhibiting tyrosine kinase signal transduction. The present invention is also directed to methods of regulating, modulating or inhibiting tyrosine kinases, whether of the receptor or non-receptor class, for the prevention and/or treatment of disorders related to unregulated tyrosine kinase signal transduction, including cell proliferative and metabolic disorders.

2. BACKGROUND OF THE INVENTION

[0003] Protein tyrosine kinases (PTKs) comprise a large and diverse class of proteins having enzymatic activity. The PTKs play an important role in the control of cell growth and differentiation (for review, see Schlessinger & Ullrich, 1992, *Neuron* 9:383-391).

[0004] For example, receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signalling molecules that facilitate the appropriate cellular response (e.g., cell division, metabolic effects to the extracellular microenvironment). See, Schlessinger and Ullrich, 1992, *Neuron* 9:303-391.

[0005] With respect to receptor tyrosine kinases, it has been shown also that tyrosine phosphorylation sites function as high-affinity binding sites for SH2 (*src* homology) domains of signaling molecules. Fantl *et al.*, 1992, *Cell* 69:413-423; Songyang *et al.*, 1994, *Mol. Cell. Biol.* 14:2777-2785; Songyang *et al.*, 1993, *Cell* 72:767-778; and Koch *et al.*, 1991, *Science* 252:668-678. Several intracellular substrate proteins that associate with receptor tyrosine kinases (RTKs) have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such domain but serve as adapters and associate with catalytically active molecules. Songyang *et al.*, 1993, *Cell* 72:767-778. The specificity of the interactions between receptors or proteins and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles. Songyang *et al.*, 1993, *Cell* 72:767-778. These observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.

[0006] Aberrant expression or mutations in the PTKs have been shown to lead to either uncontrolled cell proliferation (e.g. malignant tumor growth) or to defects in key developmental processes. Consequently, the biomedical community has expended significant resources to discover the specific biological role of members of the PTK family, their function in differentiation processes, their involvement in tumorigenesis and in other diseases, the biochemical mechanisms underlying their signal transduction pathways activated upon ligand stimulation and the development of novel drugs.

[0007] Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular).

[0008] **Receptor Tyrosine Kinases.** The RTKs comprise a large family of transmembrane receptors with diverse biological activities. The intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular responses. Ullrich & Schlessinger, 1990, *Cell* 61:203-212.

[0009] At present, at least nineteen (19) distinct RTK subfamilies have been identified. One RTK subfamily, designated the HER subfamily, is believed to be comprised of EGFR, HER2, HER3 and HER4. Ligands to the Her subfamily of receptors include epithelial growth factor (EGF), TGF- α , amphiregulin, HB-EGF, betacellulin and heregulin.

[0010] A second family of RTKs, designated the insulin subfamily, is comprised of the INS-R, the IGF-1R and the IR-R. A third family, the "PDGF" subfamily includes the PDGF α and β receptors, CSF1R, c-kit and FLK-II. Another subfamily of RTKs, identified as the FLX family, is believed to be comprised of the Kinase insert Domain-Receptor fetal liver kinase-1 (KDR/FLK-1), the fetal liver kinase 4 (FLK-4) and the *fms*-like tyrosine kinase 1 (*flt-1*). Each of these receptors was initially believed to be receptors for hematopoietic growth factors. Two other subfamilies of RTKs have been designated as the FGF receptor family (FGFR1, FGFR2, FGFR3 and FGFR4) and the Met subfamily (c-met and Ron).

EP 0 934 931 A2

[0011] Because of the similarities between the PDGF and FLX subfamilies, the two subfamilies are often considered together. The known RTK subfamilies are identified in Plowman *et al.*, 1994, *DN&P* 7(6) :334-339, which is incorporated herein by reference.

[0012] **The Non-Receptor Tyrosine Kinases.** The non-receptor tyrosine kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences. At present, over twenty-four individual non-receptor tyrosine kinases, comprising eleven (11) subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack and LIMK) have been identified. At present, the Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs and include Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The Src subfamily of enzymes has been linked to oncogenesis. A more detailed discussion of non-receptor tyrosine kinases is provided in Bolen, 1993, *Oncogene* 8:2025-2031, which is incorporated herein by reference.

[0013] Many of the tyrosine kinases, whether an RTK or non-receptor tyrosine kinase, have been found to be involved in cellular signaling pathways leading to cellular signal assays signalling pathways leading to pathogenic conditions, including cancer, psoriasis and hyper immune response.

[0014] **Development Of Compounds To Modulate The PTKs.** In view of the surmised importance of PTKs to the control, regulation and modulation of cell proliferation the diseases and disorders associated with abnormal cell proliferation, many attempts have been made to identify receptor and non-receptor tyrosine kinase "inhibitors" using a variety of approaches, including the use of mutant ligands (U.S. Application No. 4,966,849), soluble receptors and antibodies (Application No. WO 94/10202; Kendall & Thomas, 1994, *Proc. Nat'l Acad. Sci* 90:10705-09; Kim, *et al.*, 1993, *Nature* 362:841-844), RNA ligands (Jellinek, *et al.*, *Biochemistry* 33:10450-56); Takano, *et al.*, 1993, *Mol. Bio. Cell* 4:358A; Kinsella, *et al.*, 1992, *Exp. Cell Res.* 199:56-62; Wright, *et al.*, 1992, *J. Cellular Phys.* 152:448-57) and tyrosine kinase inhibitors (WO 94/03427; WO 92/21660; WO 91/15495; WO 94/14808; U.S. Patent No. 5,330,992; Mariani, *et al.*, 1994, *Proc. Am. Assoc. Cancer Res.* 35:2268).

[0015] More recently, attempts have been made to identify small molecules which act as tyrosine kinase inhibitors. For example, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642), vinyene-azaindele derivatives (PCT WO 94/14808) and 1-cyclopropyl-4-pyridyl-quinolones (U.S. Patent No. 5,330,992) have been described generally as tyrosine kinase inhibitors. Styryl compounds (U.S. Patent No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT WO 94/03427), tricyclic polyhydroxylic compounds (PCT WO 92/21660) and benzylphosphonic acid compounds (PCT WO 91/15495) have been described as compounds for use as tyrosine kinase inhibitors for use in the treatment of cancer.


[0016] The identification of effective small compounds which specifically inhibit signal transduction by modulating the activity of receptor and non-receptor tyrosine kinases to regulate and modulate abnormal or inappropriate cell proliferation is therefore desirable and the object of this invention.

3. SUMMARY OF THE INVENTION

[0017] The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting tyrosine kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated TKS transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes.

[0018] In one illustrative embodiment, the compounds of the present invention have the formula:

(I)



and pharmaceutically acceptable salts thereof, wherein

R_1 is H or alkyl;
 R_2 is O or S;

EP 0 934 931 A2

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

R₃, R₅, and R₆ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

n is 0-3;


X is Br, Cl, F or I;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl.

[0019] In another illustrative embodiment, the compounds of the present invention have the formula:

(II)



and pharmaceutically acceptable salts thereof, wherein

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

R₂, R₃, R₅, and R₆ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

Ra and Rb are each independently selected from the group consisting of H, alkyl and C(O)R, or NRaRb taken together may be a heterocyclic ring of from 3 to 8 atoms optionally substituted at one or more positions with hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

n is 0-3;

X is Br, Cl, F or I;


R is H, alkyl or aryl; and

R' is H, alkyl or aryl.

[0020] In yet another illustrative embodiment, the compounds of the present invention have the formula:

EP 0 934 931 A2

(III)



and pharmaceutically acceptable salts thereof, wherein

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

A is a five membered heteroaryl ring selected from the group consisting of thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3,4-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,2,3,4-thiatriazole, 1,2,3,5-thiatriazole, and tetrazole, optionally substituted at one or more positions with alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R or CONRR';

n is 0-3;


X is Br, Cl, F or I;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl.

[0021] In still another illustrative embodiment, the compounds of the present invention have the formula:

(IV)



and pharmaceutically acceptable salts thereof, wherein:

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

R₃, R₄, R₅, and R₆ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R,

EP 0 934 931 A2

OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

n is 0-3;


X is Br, Cl, F or I;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl.

[0022] In a final illustrative embodiment, the compounds of the present invention have the formula:

(V)



and pharmaceutically acceptable salts thereof, wherein:

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R and CONRR';

R₂', R₃', R₅', and R₆' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R and CONRR';

n is 0-3;

Z is Br, Cl, F, I, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl.

[0023] The present invention is further directed to pharmaceutical compositions comprising a pharmaceutically effective amount of the above-described compounds of formulae I-V and a pharmaceutically acceptable carrier or excipient. Such a composition is believed to modulate signal transduction by a tyrosine kinase, either by inhibition of catalytic activity, affinity to ATP or ability to interact with a substrate.

[0024] More particularly, the compositions of the present invention may be included in methods for treating diseases comprising proliferation, fibrotic or metabolic disorders, for example cancer, fibrosis, psoriasis, atherosclerosis, arthritis, and other disorders related to abnormal vasculogenesis and/or angiogenesis, such as diabetic retinopathy.

4. DETAILED DESCRIPTION OF THE INVENTION

4.1. Definitions

[0025] "Pharmaceutically acceptable salt" refers to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

[0026] "Alkyl" refers to a straight-chain, branched or cyclic saturated aliphatic hydrocarbon. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like. The alkyl group may be optionally substituted with one or more substituents are selected from the group consisting of hydroxyl, cyano, alkoxy, =O, =S, NO₂, halogen, N(CH₃)₂ amino, and SH.

EP 0 934 931 A2

[0027] "Alkenyl" refers to a straight-chain, branched or cyclic unsaturated hydrocarbon group containing at least one carbon-carbon double bond. Preferably, the alkenyl group has 1 to 12 carbons. More preferably it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, cyano, alkoxy, =O, =S, NO₂, halogen, N(CH₃)₂ amino, and SH.

[0028] "Alkynyl" refers to a straight-chain, branched or cyclic unsaturated hydrocarbon containing at least one carbon-carbon triple bond. Preferably, the alkynyl group has 1 to 12 carbons. More preferably it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, cyano, alkoxy, =O, =S, NO₂, halogen, N(CH₃)₂ amino, and SH.

[0029] "Alkoxy" refers to an "-Oalkyl" group.

[0030] "Aryl" refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups. The aryl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl, hydroxyl, SH, OH, NO₂, amine, thioether, cyano, alkoxy, alkyl, and amino.

[0031] "Alkaryl" refers to an alkyl that is covalently joined to an aryl group. Preferably, the alkyl is a lower alkyl.

[0032] "Carbocyclic aryl" refers to an aryl group wherein the ring atoms are carbon.

[0033] "Heterocyclic aryl" refers to an aryl group having from 1 to 3 heteroatoms as ring atoms, the remainder of the ring atoms being carbon. Heteroatoms include oxygen, sulfur, and nitrogen. Thus, heterocyclic aryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like.

[0034] "Amide" refers to -C(O)-NH-R, where R is alkyl, aryl, alkylaryl or hydrogen.

[0035] "Thioamide" refers to -C(S)-NH-R, where R is alkyl, aryl, alkylaryl or hydrogen.

[0036] "Amine" refers to a -N(R')R" group, where R' and R" are independently selected from the group consisting of alkyl, aryl, and alkylaryl.

[0037] "Thioether" refers to -S-R, where R is alkyl, aryl, or alkylaryl.

[0038] "Sulfonyl" refers to -S(O)₂-R, where R is aryl, C(CN)=C-aryl, CH₂CN, alkylaryl, sulfonamide, NH-alkyl, NH-alkylaryl, or NH-aryl.

4.2. The Invention

[0039] The present invention relates to compounds capable of regulating and/or modulating tyrosine kinase signal transduction and more particularly receptor and non-receptor tyrosine kinase signal transduction.

[0040] Receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signalling molecules that facilitate the appropriate cellular response (e.g., cell division, metabolic effects to the extracellular microenvironment). See, Schlessinger and Ullrich, 1992, *Neuron* 9:303-391.

[0041] It has been shown that tyrosine phosphorylation sites in growth factor receptors function as high-affinity binding sites for SH2 (*src* homology) domains of signaling molecules. Fantl *et al.*, 1992, *Cell* 69:413-423; Songyang *et al.*, 1994, *Mol. Cell. Biol.* 14:2777-2785; Songyang *et al.*, 1993, *Cell* 72:767-778; and Koch *et al.*, 1991, *Science* 252:668-678. Several intracellular substrate proteins that associate with receptor tyrosine kinases have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such domain but serve as adapters and associate with catalytically active molecules. Songyang *et al.*, 1993, *Cell* 72:767-778. The specificity of the interactions between receptors and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles. Songyang *et al.*, 1993, *Cell* 72:767-778. These observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.

[0042] Tyrosine kinase signal transduction results in, among other responses, cell proliferation, differentiation and metabolism. Abnormal cell proliferation may result in a wide array of disorders and diseases, including the development of neoplasia such as carcinoma, sarcoma, leukemia, glioblastoma, hemangioma, psoriasis, arteriosclerosis, arthritis and diabetic retinopathy (or other disorders related to uncontrolled angiogenesis and/or vasculogenesis).

[0043] This invention is therefore directed to compounds which regulate, modulate and/or inhibit tyrosine kinase signal transduction by affecting the enzymatic activity of the RTKs and/or the non-receptor tyrosine kinases and interfering


EP 0 934 931 A2

with the signal transduced such proteins. More particularly, the present invention is directed to compounds which regulate, modulate and/or inhibit the RTK and/or non-receptor tyrosine kinase mediated signal transduction pathways as a therapeutic approach to cure many kinds of solid tumors, including but not limited to carcinoma, sarcoma, leukemia, erythroblastoma, glioblastoma, meningioma, astrocytoma, melanoma and myoblastoma. Indications may include, but are not limited to brain cancers, bladder cancers, ovarian cancers, gastric cancers, pancreas cancers, colon cancers, blood cancers, lung cancers and bone cancers.

4.3. The Compounds

[0044] In one embodiment, the invention provides compounds having the formula:

(I)



and the pharmaceutically acceptable salts thereof, wherein

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

R₃', R₅', and R₆' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

n is 0-3;

X is Br, Cl, F or I; and

R is H, alkyl or aryl; and

R' is H, alkyl or aryl.


[0045] In a preferred embodiment of the compounds of formula I, R₃' is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl; and R₅' is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl.

[0046] A particularly preferred compound of formula I is 3-(2-chloro-4-hydroxybenzylidenyl)-2-indolinone.

[0047] In another embodiment, the invention provides compounds having the formula:

EP 0 934 931 A2

(II)



and the pharmaceutically acceptable salts thereof, wherein

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

R₂, R₃, R₅, and R₆ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

Ra and Rb are each independently selected from the group consisting of H, alkyl and C(O)R, or NRaRb taken together may be a heterocyclic ring of from 3 to 8 atoms optionally substituted at one or more positions with hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, or CONRR';

n is 0-3;

X is Br, Cl, F or I; and

R is H, alkyl or aryl; and


R' is H, alkyl or aryl.

[0048] In a preferred embodiment of the compounds of formula II, R₃' is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl; and R₅' is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl.

[0049] A particularly preferred compound of formula II is 3-(4-Dimethylaminobenzylidenyl)-2-indolinone.

[0050] In yet another embodiment, the invention provides compounds having the formula:

(III)



and the pharmaceutically acceptable salts thereof, wherein

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, ary-

EP 0 934 931 A2

loxy, alkaryl, alkarylloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

A is a five membered heteroaryl ring selected from the group consisting of thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3,4-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,2,3,4-thiatriazole, 1,2,3,5-thiatriazole, and tetrazole, optionally substituted at one or more positions with alkyl, alkoxy, aryl, aryloxy, alkaryl, alkarylloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R or CONRR';

n is 0-3;

X is Br, Cl, F or I;


R is H, alkyl or aryl; and

R' is H, alkyl or aryl.

[0051] In a preferred embodiment of the invention, the compound of formula III is 3-[(2,3-Dimethylpyrrol-5-yl)methylene]-2-indolinone.

[0052] In still another embodiment, the invention provides compounds having the formula:

(IV)



and the pharmaceutically acceptable salts thereof, wherein:

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkarylloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

R₃', R₄', R₅', and R₆' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkarylloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

n is 0-3;

X is Br, Cl, F or I;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl.


[0053] In a preferred embodiment of the compound of formula IV, R₃' is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl; and R₅' is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl.

[0054] A particularly preferred compound of formula IV is 3-(2-Ethoxybenzylidenyl)-2-indolinone.

[0055] In a final embodiment, the invention provides compounds having the formula:

EP 0 934 931 A2

(V)



15 and the pharmaceutically acceptable salts thereof, wherein:

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

20 R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R and CONRR';

25 R₂, R₃, R₅, and R₆ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R and CONRR';

n is 0-3;

Z is Br, Cl, F, I, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl.

30 [0056] In a preferred embodiment of the compounds of formula V, R₃' is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl; and R₅' is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl.

35 [0057] A particularly preferred compound of formula V is 3-(4-Bromobenzylidene)-2-indolinone.

[0058] The chemical formulae referred herein may exhibit the phenomena of tautomerism or structural isomerism. For example, the compounds described herein may be adopt a *cis* or *trans* conformation about the double bond connecting the indolinone 3-substituent to the indolinone ring, or may be mixtures of *cis* and *trans* isomers. As the formulae drawing within this specification can only represent one possible tautomeric or structural isomeric form, it should be understood that the invention encompasses any tautomeric or structural isomeric form, or mixtures thereof, which possesses the ability to regulate, inhibit and/or modulate tyrosine kinase signal transduction or cell proliferation and is not limited to any one tautomeric or structural isomeric form utilized within the formulae drawing.

40 [0059] In addition to the above-described compounds and their pharmaceutically acceptable salts, the invention is further directed, where applicable, to solvated as well as unsolvated forms of the compounds (e.g. hydrated forms) having the ability to regulate and/or modulate cell proliferation.

45 [0060] The compounds described herein may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Suitable processes are illustrated in the examples. Necessary starting materials may be obtained by standard procedures of organic chemistry.

50 [0061] An individual compound's relevant activity and efficacy as an agent to affect receptor tyrosine kinase mediated signal transduction may be determined using available techniques. Preferentially, a compound is subjected to a series of screens to determine the compound's ability to modulate, regulate and/or inhibit cell proliferation. These screens, in the order in which they are conducted, include biochemical assays, cell growth assays and *in vivo* experiments.

4.4. Indications

55 [0062] The compounds described herein are useful for treating disorders related to unregulated tyrosine kinase signal transduction, including cell proliferative disorders, fibrotic disorders and metabolic disorders.

[0063] Cell proliferative disorders which can be treated or further studied by the present invention include cancers,

EP 0 934 931 A2

blood vessel proliferative disorders and mesangial cell proliferative disorders.

[0064] Blood vessel proliferative disorders refer to angiogenic and vasculogenic disorders generally resulting in abnormal proliferation of blood vessels. The formation and spreading of blood vessels, or vasculogenesis and angiogenesis, respectively, play important roles in a variety of physiological processes such as embryonic development, corpus luteum formation, wound healing and organ regeneration. They also play a pivotal role in cancer development. Other examples of blood vessel proliferation disorders include arthritis, where new capillary blood vessels invade the joint and destroy cartilage, and ocular diseases, like diabetic retinopathy, where new capillaries in the retina invade the vitreous, bleed and cause blindness. Conversely, disorders related to the shrinkage, contraction or closing of blood vessels, such as restenosis, are also implicated.

[0065] Fibrotic disorders refer to the abnormal formation of extracellular matrix. Examples of fibrotic disorders include hepatic cirrhosis and mesangial cell proliferative disorders. Hepatic cirrhosis is characterized by the increase in extracellular matrix constituents resulting in the formation of a hepatic scar. Hepatic cirrhosis can cause diseases such as cirrhosis of the liver. An increased extracellular matrix resulting in a hepatic scar can also be caused by viral infection such as hepatitis. Lipocytes appear to play a major role in hepatic cirrhosis. Other fibrotic disorders implicated include atherosclerosis (see, below).

[0066] Mesangial cell proliferative disorders refer to disorders brought about by abnormal proliferation of mesangial cells. Mesangial proliferative disorders include various human renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection, and glomerulopathies. The PDGF-R has been implicated in the maintenance of mesangial cell proliferation. Floege *et al.*, 1993, *Kidney International* 43:47S-54S.

[0067] PTKs have been associated with such cell proliferative disorders. For example, some members of the RTK family have been associated with the development of cancer. Some of these receptors, like the EGFR (Tuzi *et al.*, 1991, *Br. J. Cancer* 63:227-233; Torp *et al.*, 1992, *APMIS* 100:713-719) HER2/neu (Slamon *et al.*, 1989, *Science* 244:707-712) and the PDGF-R (Kumabe *et al.*, 1992, *Oncogene* 7:627-633) are overexpressed in many tumors and/or persistently activated by autocrine loops. In fact, in the most common and severe cancers these receptor overexpressions (Akbasak and Suner-Akbasak *et al.*, 1992, *J. Neurol. Sci.* 111:119-133; Dickson *et al.*, 1992, *Cancer Treatment Res.* 61:249-273; Korc *et al.*, 1992, *J. Clin. Invest.* 90:1352-1360) and autocrine loops (Lee and Donoghue, 1992, *J. Cell. Biol.* 118:1057-1070; Korc *et al.*, *supra*; Akbasak and Suner-Akbasak *et al.*, *supra*) have been demonstrated. For example, the EGFR receptor has been associated with squamous cell carcinoma, astrocytoma, glioblastoma, head and neck cancer, lung cancer and bladder cancer. HER2 has been associated with breast, ovarian, gastric, lung, pancreas and bladder cancer. The PDGF-R has been associated with glioblastoma, lung, ovarian, melanoma and prostate. The RTK c-met has been generally associated with hepatocarcinogenesis and thus hepatocellular carcinoma. Additionally, c-met has been linked to malignant tumor formation. More specifically, the RTK c-met has been associated with, among other cancers, colorectal, thyroid, pancreatic and gastric carcinoma, leukemia and lymphoma. Additionally, overexpression of the c-met gene has been detected in patients with Hodgkins disease, Burkitts disease, and the lymphoma cell line.

[0068] The IGF-IR, in addition to being implicated in nutritional support and in type-II diabetes, has also been associated with several types of cancers. For example, IGF-I has been implicated as an autocrine growth stimulator for several tumor types, e.g. human breast cancer carcinoma cells (Arteaga *et al.*, 1989, *J. Clin. Invest.* 84:1418-1423) and small lung tumor cells (Macauley *et al.*, 1990, *Cancer Res.* 50:2511-2517). In addition, IGF-I, integrally involved in the normal growth and differentiation of the nervous system, appears to be an autocrine stimulator of human gliomas. Sandberg-Nordqvist *et al.*, 1993, *Cancer Res.* 53:2475-2478. The importance of the IGF-IR and its ligands in cell proliferation is further supported by the fact that many cell types in culture (fibroblasts, epithelial cells, smooth muscle cells, T-lymphocytes, myeloid cells, chondrocytes, osteoblasts, the stem cells of the bone marrow) are stimulated to grow by IGF-I. Goldring and Goldring, 1991, *Eukaryotic Gene Expression* 1:301-326. In a series of recent publications, Baserga even suggests that IGF-I-R plays a central role in the mechanisms of transformation and, as such, could be a preferred target for therapeutic interventions for a broad spectrum of human malignancies. Baserga, 1995, *Cancer Res.* 55:249-252; Baserga, 1994, *Cell* 79:927-930; Coppola *et al.*, 1994, *Mol. Cell. Biol.* 14:4588-4595.

[0069] The association between abnormalities in RTKs and disease are not restricted to cancer, however. For example, RTKs have been associated with metabolic diseases like psoriasis, diabetes mellitus, wound healing, inflammation, and neurodegenerative diseases. For example, the EGF-R is indicated in corneal and dermal wound healing. Defects in the Insulin-R and the IGF-1R are indicated in type-II diabetes mellitus. A more complete correlation between specific RTKs and their therapeutic indications is set forth in Plowman *et al.*, 1994, *DN&P* 7:334-339.

[0070] Not only receptor type tyrosine kinases, but also many cellular tyrosine kinases (CTKs) including src, abl; fps, yes, fyn, lyn, lck, blk, hck, fgr, yrk (reviewed by Bolen *et al.*, 1992, *FASEB J.* 6:3403-3409) are involved in the proliferative and metabolic signal transduction pathway and thus in indications of the present invention. For example, mutated src (v-src) has been demonstrated as an oncoprotein (pp60^{v-src}) in chicken. Moreover, its cellular homolog, the proto-oncogene pp60^{c-src} transmits oncogenic signals of many receptors. For example, overexpression of EGF-R or

EP 0 934 931 A2

HER2/neu in tumors leads to the constitutive activation of pp60^{c-src}, which is characteristic for the malignant cell but absent from the normal cell. On the other hand, mice deficient for the expression of c-src exhibit an osteopetrotic phenotype, indicating a key participation of c-src in osteoclast function and a possible involvement in related disorders. Similarly, Zap 70 is implicated in T-cell signalling.

5 [0071] Furthermore, the identification of CTK modulating compounds to augment or even synergize with RTK aimed blockers is an aspect of the present invention.

[0072] Finally, both RTKs and non-receptor type kinases have been connected to hyperimmune disorders.

4.5. Pharmaceutical Formulations And Routes Of Administration

10 [0073] The compounds described herein can be administered to a human patient *per se*, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s). Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition.

4.5.1. Routes Of Administration.

15 [0074] Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.

20 [0075] Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a solid tumor, often in a depot or sustained release formulation.

[0076] Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with tumor-specific antibody. The liposomes will be targeted to and taken up selectively by the tumor.

4.5.2. Composition/Formulation.

25 [0077] The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

30 [0078] Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

35 [0079] For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

40 [0080] For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

45 [0081] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

50 [0082] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

EP 0 934 931 A2

[0083] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0084] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of *e.g.* gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0085] The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

[0086] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0087] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

[0088] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

[0089] In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0090] A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, *e.g.* polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.

[0091] Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

[0092] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[0093] Many of the PTK modulating compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protic solvents than are the corresponding free base forms.

EP 0 934 931 A2

4.5.3. Effective Dosage.

[0094] Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

[0095] For any compound used in the methods of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC_{50} as determined in cell culture (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of the PTK activity). Such information can be used to more accurately determine useful doses in humans.

[0096] Toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD_{50} (the dose lethal to 50% of the population) and the ED_{50} (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD_{50} and ED_{50} . Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED_{50} with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See *e.g.*, Fingl *et al.*, 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1).

[0097] Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the kinase modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from *in vitro* data; *e.g.*, the concentration necessary to achieve 50-90% inhibition of the kinase using the assays described herein. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

[0098] Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.

[0099] In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

[0100] The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

4.5.4. Packaging

[0101] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labelled for treatment of an indicated condition. Suitable conditions indicated on the label may include treatment of a tumor, inhibition of angiogenesis, treatment of fibrosis, diabetes, and the like.

5. EXAMPLE: Compound Synthesis

[0102] The compounds of the present invention may be synthesized according to known techniques. The following represent preferred methods for synthesizing the compounds of the claimed invention.

5.1. General Syntheses of 3-Substituted-2-Indolinone Analogs

[0103] The following general methodologies were used to synthesize 3-substituted-2-indolinone compounds of the invention.

EP 0 934 931 A2

5.1.1. Method A

[0104] A reaction mixture of the proper oxindole (2-indolinone) (1 equiv.), the appropriate aldehyde (1.2 equiv.), and piperidine (0.1 equiv.) in ethanol (1 - 2 mL / 1 mmol oxindole) was stirred at 90°C for 3 - 5 h. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield the target compound.

5.1.2. Method B

[0105] **Preparation of The Proper Aldehydes via Vilsmeier Reaction.** To a solution of N,N-dimethylformamide (1.2 equiv.) in 1,2-dichloroethane (2.0 mL / 1.0 mmole of starting material) was added dropwise phosphorus oxychloride (1.2 equiv.) at 0°C. The ice-bath was removed and the reaction mixture was further stirred for 30 min. The proper starting material (1.0 equiv.) was added to the above solution portionwise and the reaction mixture was stirred at 50-70°C for 5 h - 2 days. The reaction mixture was poured into ice-cold 1N sodium hydroxide solution (pH = 9 after mixing) and the resulting mixture was stirred at room temperature for 1 h. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine until pH = 7, dried over anhydrous sodium sulfate and evaporated. The residue was chromatographed on a silica gel column eluting with a solvent mixture of ethyl acetate and hexane to afford the title compound.

[0106] **Synthesis for 3-Substituted-2-Indolinone Analogs.** A reaction mixture of the proper oxindole (2-indolinone) (1 equiv.), the appropriate aldehyde (1.2 equiv.), and piperidine (0.1 equiv.) in ethanol (1 - 2 mL / 1 mmol oxindole) was stirred at 90°C for 3 - 5 h. After cooling, the precipitate was filtered, washed with cold ethanol and dried to yield the target compound.

5.2. Synthesis Of 3-Benzylidene-2-Indolinone

[0107] The preferred method for synthesizing 3-benzylidene-2-indolinone is as follows: Added 123.2 µl of benzaldehyde and 40 µl of piperidine to a solution of 137.0 mg of oxindole in 2.0 ml methanol. Reflux the reaction mixture for 3 hours and cool down the mixture in an ice-water bath. Filter the resulting precipitate, wash with cold methanol and dry in an oven at 40°C overnight. Approximately 129.0 mg of the compound was obtained using such protocol.

5.3. Synthesis Of 3-[(Pyrid-4-yl) methylene]-2-indolinone

[0108] The preferred method for synthesizing 3-[(Pyrid-4-yl)methylene]-2-indolinone as follows: Add 117.0 µl of 4-pyridinecarboxaldehyde and 40 µl of piperidine to a solution of 138.0 mg of oxindole in 2.0 ml methanol. The reaction mixture was refluxed for 3 hours and cooled down in an ice-water bath. The resulting precipitate was filtered, washed with cold methanol and dried in an oven at 40°C overnight to give 134.5 mg of the compound.

5.4. Synthesis of 3-[4-(morpholin-4-yl)benzylidenyl]-2-indolinone (Method B):

[0109] **4-(Morpholin-4-yl)benzaldehyde.** To a solution of 15 mL of N,N-dimethylformamide in 50 mL of 1,2-dichloroethane was added dropwise 10 mL of phosphorus oxychloride at 0°C. The ice-bath was removed and the reaction mixture was further stirred for 30 min. 4-Phenylmorpholine (16.3 g) was added to the above solution portionwise and the reaction mixture was refluxed for 2 days. Triethylamine (2.5 mL) was added to the above reaction mixture and the reaction was refluxed for 2 day. The reaction mixture was poured into ice-cold 1N sodium hydroxide solution (pH = 9 after mixing) and the resulting mixture was stirred at room temperature for 1 h. The organic layer was separated and the aqueous layer was extracted with 2 x 20 mL of dichloromethane. The combined organic layer was washed with brine until pH = 7, dried over anhydrous sodium sulfate and evaporated. The residue was separated on a silica gel column eluting with a solvent mixture of ethyl acetate and hexane to afford 12.95 g (68%) of the title compound as a white solid.

[0110] **3-[4-(Morpholin-4-yl)benzylidenyl]-2-indolinone.** A reaction mixture of 6.66 g of oxindole, 11.50 g of the 4-(morpholine-4-yl)benzaldehyde, and 5 mL of piperidine in 50 mL of ethanol was stirred at 90°C for 5 h. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield 15.0 g (98%) of the title compound as a yellow solid.

5.5. Synthesis of 3-[4-(4-Formylpiperazin-1-yl)benzylidenyl]-2-indolinone (Method B):

[0111] **4-(4-Formylpiperazin-1-yl)benzaldehyde.** To a solution of 3.9 mL (30 mmoles) of N,N-dimethylformamide in 20 mL of 1,2-dichloroethane was added dropwise 3.0 mL (3.9 mmoles) of phosphorus oxychloride at 0°C. The ice-bath was removed and the reaction mixture was further stirred for 15 min. 1-Phenylpiperazine (16.0 g, 10 mmoles) was added to the above solution portionwise and the reaction mixture was stirred at 50°C for 1 h. The reaction mixture was

EP 0 934 931 A2

poured into ice-cold 1N sodium hydroxide solution and stirred at room temperature for 1 h. The organic layer was separated and the aqueous layer was extracted with 2 x 20 mL of ethyl acetate. The combined organic layer was washed with brine until pH = 7, dried over anhydrous sodium sulfate and evaporated. The residue was separated on a silica gel column eluting with a mixture of ethyl acetate and hexane to afford 9.0 g (41%) of the title compound a light yellow solid.

5 [0112] 3-[4-(4-Formylpiperazin-1-yl)benzylidenyl]-2-indolinone. A reaction mixture of 133.15 mg of oxindole, 228.3 mg of 4-(piperazin-1-yl)benzaldehyde, and 3 drops of piperidine in 2 mL of ethanol was stirred at 90°C for 5 h. After cooling, the precipitate was filtered, washed with cold ethanol and dried to yield 199.5 mg (65%) of the title compound a yellow solid.

10 5.6. Synthesis of 3-[4-(Piperidin-1-yl)benzylidenyl]-2-Indolinone (Method B).

[0113] 4-(Piperidin-1-yl)benzaldehyde. To a solution of 2.3 mL (30 mmoles) of N,N-dimethylformamide in 10 mL of 1,2-dichloroethane was added dropwise 2.8 mL (30 mmoles) of phosphorus oxychloride at 0°C. The ice-bath was removed and the reaction mixture was stirred for 15 min. 1-Phenylpiperidine (3.2 mL, 20 mmoles) was added to the
15 above solution portionwise and the reaction mixture was refluxed overnight. The reaction mixture was poured into ice-cold 2N sodium hydroxide solution and stirred at room temperature for 1 h. The organic layer was separated and the aqueous layer was extracted with 2 x 20 mL of ethyl acetate. The combined organic layer was washed with brine until pH = 7, dried over anhydrous sodium sulfate and evaporated. The residue was separated on a silica gel column eluting with ethyl acetate and hexane to afford 1.5 g (40%) of the title compound as a white solid.

20 [0114] 3-[4-(Piperidin-1-yl)benzylidenyl]-2-Indolinone. A reaction mixture of 134.9 mg of oxindole, 226.8 g of 4-(piperidine-1-yl)benzaldehyde, and 3 drops of piperidine in 2 mL of ethanol was stirred at 90°C for 5 h. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield 268.5 mg (88%) of the title compound as a yellow solid.

25 5.7. Synthesis of 3-[2-Chloro-4-methoxybenzylidenyl]-2-indolinone.

[0115] 2-Chloro-4-methoxybenzaldehyde. The reaction mixture of 1.0 g (6.4 mmoles) of 2-chloro-4-hydroxybenzaldehyde, 4.4 g (32 mmoles) of potassium carbonate, and 1.4 g (9.6 mmoles) of methyl iodide in 10 mL of N,N-dimethylformamide was stirred at 70°C for 2 h and poured into ice water. The precipitate was filtered, washed with water, and
30 dried at 40°C in vacuum oven overnight to yield 750 mg (68%) of the title compound as a light pink solid.

[0116] 3-[2-chloro-4-methoxybenzylidenyl]-2-Indolinone. The reaction mixture of 487.9 mg (3.7 mmoles) of oxindole, 750 mg (4.3 mmoles) of 2-chloro-4-methoxybenzaldehyde and 4 drops of piperidine in 5 mL of ethanol was heated to 90°C for 2 h and cooled to room temperature. The yellow precipitate was filtered, washed with cold ethanol, and dried at 40°C in a vacuum oven overnight to give 680.2 mg (62%) of the title compound.

35 5.8. Synthesis of 3-[(4-Methylthien-2-yl)methylene]-2-indolinone.

[0117] A reaction mixture of 133.0 mg of oxindole, 151.2 mg of the 4-methylthiophene-2-carboxaldehyde, and 3 drops of piperidine in 3 mL of ethanol was stirred at 90°C for 3 h. After cooling, the precipitate was filtered, washed with cold
40 ethanol, and dried to yield 147.3 mg (61%) of the title compound as a yellow solid.

5.9. Synthesis of 3-[(3-Methylpyrrol-2-yl)methylene]-2-Indolinone.

[0118] A reaction mixture of 133.0 mg of oxindole, 130.9 mg of the 3-methylpyrrole-2-carboxaldehyde, and 3 drops of
45 piperidine in 2 mL of ethanol was stirred at 90°C for 3 h. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield 150.9 mg (67%) of the title compound as a yellow solid.

5.10. Synthesis of 3-[(3,4-Dimethylpyrrol-2-yl)methylene]-2-indolinone

50 [0119] 3-[(3,4-Dimethylpyrrol-2-yl)methylene]-2-indolinone was synthesized as described in J. Heterocyclic Chem. 13:1145-1147 (1976).

[0120] Ethyl 4-methylpyrrol-3-carboxylate. A solution of 11.86 g (0.1 moles) of ethyl crotonate and 19.50 g (0.1 moles) of *p*-toluenesulfonylmethylisocyanide in 500 mL of a 2:1 ether/dimethylsulfoxide was added dropwise into a suspension of 6.8 g of sodium hydride (60% mineral oil dispersion, 0.17 moles) in ether at room temperature. Upon completion of addition the reaction mixture was stirred for 30 min and dilute with 400 mL of water. The aqueous layer was
55 extracted with 3x100 mL of ether. The combined ether extracts were passed through a column of alumina eluting with dichloromethane. The organic solvent was evaporated and the resulting residue was solidified on standing. The solid was washed with hexane and dried at 40°C in vacuum oven overnight to yield 12.38 g (80%) of the title compound.

EP 0 934 931 A2

[0121] **Preparation of 3,4-Dimethylpyrrole.** To a solution of 23 g (80 mmoles) of sodium dihydrobis (2-methoxyethoxy aluminate) was added dropwise of a solution of 5 g (34 mmoles) of ethyl 4-methylpyrrol-3-carboxylate in 50 mL of benzene at room temperature under nitrogen atmosphere. The reaction mixture was stirred for 18 h. Water (100 mL) was added to the reaction mixture. The organic layer was separated, washed with brine and dried over anhydrous sodium sulfate. The solvent was removed and the residue was distilled giving 1.2 g (44%) of the title compound.

[0122] **Preparation of 3,4-Dimethylpyrrole-2-carboxaldehyde.** To a solution of 0.92 mL (12 mmoles) of N,N-dimethylformamide in 10 mL of 1,2-dichloroethane was added dropwise 1.0 mL (12 mmoles) of phosphorus oxychloride at 0°C. The ice-bath was removed and the reaction mixture was further stirred for 30 min. 3,4-Dimethylpyrrole (960.0 mg, 10 mmoles) was added to the above solution portionwise and the reaction mixture was stirred at 50°C for 5 h. The reaction mixture was poured into ice-cold 1N sodium hydroxide solution (pH = 9 after mixing) and the resulting mixture was stirred at room temperature for 1 h. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine until pH = 7, dried over anhydrous sodium sulfate and evaporated. The residue was chromatographed on a silica gel column eluting with a solvent mixture of ethyl acetate and hexane to afford 610 mg (50%) of the title compound.

[0123] **3-[(3,4-Dimethylpyrrol-2-yl)methylene]-2-Indoline.** A reaction mixture of 67.0 mg (0.5 mmoles) of oxindole, 73.0 mg (0.6 mmoles) of the 3,4-dimethylpyrrole-2-carboxaldehyde, and 2 drops of piperidine in 2 mL of ethanol was stirred at 90°C for 3 h. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield 87.7 mg (37%) of the title compound as a yellow solid.

5.11. Synthesis of 3-[(2,4-Dimethyl-3-ethoxycarbonylpyrrol-5-yl)methylene]-2-Indolinone

[0124] A reaction mixture of 134.0 mg of oxindole, 234.3 mg of the 4-ethoxycarbonyl-3,5-dimethylpyrrole-2-carboxaldehyde, and 3 drops of piperidine in 3 mL of ethanol was stirred at 90°C for 3 h. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield 244.6 mg (79%) of the title compound as a yellow solid.

5.12. Synthesis of 3-[(2,3-Dimethylpyrrol-5-yl)methylene]-2-Indolinone

[0125] A reaction mixture of 134.0 mg of oxindole, 147.8 mg of the 3,5-dimethylpyrrole-2-carboxaldehyde, and 3 drops of piperidine in 2 mL of ethanol was stirred at 90°C for 3 h. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield 136.7 mg (57%) of the title compound as a yellow solid.

5.13. Synthesis of 3-[(2-Methylmercaptophen-5-yl)methylene]-2-Indolinone

[0126] A reaction mixture of 134.0 mg of oxindole, 189.9 mg of the 5-methylmercaptophen-2-carboxaldehyde, and 3 drops of piperidine in 2 mL of ethanol was stirred at 90°C for 3 h. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield 246.6 mg (90%) of the title compound as an orange solid.

5.14. Synthesis of 3-[(2-Methylthien-5-yl)methylene]-2-Indolinone

[0127] A reaction mixture of 134.0 mg of oxindole, 151.42 mg of the 5-methylthiophene-2-carboxaldehyde, and 3 drops of piperidine in 2 mL of ethanol was stirred at 90°C for 3 h. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield 237.8 mg (99%) of the title compound as a yellow solid.

5.15. Synthesis of 3-[(3-Methylthien-2-yl)methylene]-2-Indolinone

[0128] A reaction mixture of 134.0 mg of oxindole, 151.4 mg of the 3-methylthiophene-2-carboxaldehyde, and 3 drops of piperidine in 2 mL of ethanol was stirred at 90°C for 3 h. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield 157.8 mg (65%) of the title compound as a yellow solid.

5.16. Synthesis of 3-(2,5-Dimethoxybenzylidenyl)-2-Indolinone

[0129] 3-(2,5-Dimethoxybenzylidenyl)-2-Indolinone is synthesized according to Method A.

5.17. Synthesis of 3-(2,3-dimethoxybenzylidenyl)-2-Indolinone

[0130] 3-(2,3-dimethoxybenzylidenyl)-2-Indolinone is synthesized according to Method A.

EP 0 934 931 A2**5.18. Synthesis of 3-(3-bromo-6-methoxybenzylidenyl)-2-indolinone**

[0131] 3-(3-bromo-6-methoxybenzylidenyl)-2-indolinone is synthesized according to Method A.

5.19. Synthesis of 3-[4-(4-t-butylcarbonyl-piperazin-1-yl)benzylidenyl]-2-indolinone

[0132] 3-[4-(4-t-butylcarbonyl-piperazin-1-yl)benzylidenyl]-2-indolinone is synthesized according to Method B.

5.20. Synthesis of 3-[(furan-2-yl)methylene]-2-indolinone

[0133] 3-[(furan-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.21. Synthesis of 3-(4-acetamidobenzylidenyl)-2-indolinone

[0134] 3-(4-acetamidobenzylidenyl)-2-indolinone is synthesized according to Method A.

5.22. Synthesis of 3-(2-chloro-4-hydroxybenzylidenyl)-2-indolinone

[0135] 3-(2-chloro-4-hydroxybenzylidenyl)-2-indolinone is synthesized according to Method A.

5.23. Synthesis of 3-(4-Bromobenzylidenyl)-2-indolinone

[0136] 3-(4-Bromobenzylidenyl)-2-indolinone is synthesized according to Method A.

5.24. Synthesis of 3-(4-Acetylaminobenzylidenyl)-2-indolinone

[0137] 3-(4-Acetylaminobenzylidenyl)-2-indolinone is synthesized according to Method A.

5.25. Synthesis of 3-(2-Methoxybenzylidenyl)-2-indolinone

[0138] 3-(2-Methoxybenzylidenyl)-2-indolinone is synthesized according to Method A.

5.26. Synthesis of 3-(4-Dimethylaminobenzylidenyl)-1-methyl-2-indolinone

[0139] 3-(4-Dimethylaminobenzylidenyl)-1-methyl-2-indolinone is synthesized according to Method A.

5.27. Synthesis of 3-(4-Dimethylaminobenzylidenyl)-2-indolinone

[0140] 3-(4-Dimethylaminobenzylidenyl)-2-indolinone is available from Maybridge Chemical Co. Ltd.

5.28. Synthesis of 3-(4-Bromobenzylidenyl)-1-methyl-2-Indolinone

[0141] 3-(4-Bromobenzylidenyl)-1-methyl-2-indolinone is synthesized according to Method A.

5.29. Synthesis of 5-Chloro-3-(4-dimethylaminobenzylidenyl)-2-Indolinone

[0142] 5-Chloro-3-(4-dimethylaminobenzylidenyl)-2-indolinone is synthesized according to Method A.

5.30. Synthesis of 3-(4-Bromobenzylidenyl)-5-chloro-2-indolinone

[0143] 3-(4-Bromobenzylidenyl)-5-chloro-2-indolinone is synthesized according to Method A.

5.31. Synthesis of 3-(4-Diethylaminobenzylidenyl)-2-indolinone

[0144] 3-(4-Diethylaminobenzylidenyl)-2-indolinone is synthesized according to Method A.

EP 0 934 931 A2**5.32. Synthesis of 3-[4-Di-n-butylaminobenzylidenyl]-2-indolinone**

[0145] 3-(4-Di-n-butylaminobenzylidenyl)-2-indolinone is synthesized according to Method A.

5.33. Synthesis of 1-Methyl-3-[4-(morpholin-4-yl)benzylidenyl]-2-indolinone

[0146] 1-Methyl-3-[4-(morpholin-4-yl)benzylidenyl]-2-indolinone is synthesized according to Method B.

5.34. Synthesis of 5-Chloro-3-(4-(morpholine-4-yl)benzylidenyl)-2-indolinone

[0147] 5-Chloro-3-(4-(morpholine-4-yl)benzylidenyl)-2-indolinone is synthesized according to Method B.

5.35. Synthesis of 3-(3,4-Dichlorobenzylidenyl)-2-indolinone

[0148] 3-(3,4-Dichlorobenzylidenyl)-2-indolinone is synthesized according to Method A.

5.36. Synthesis of 3-(2-Ethoxybenzylidenyl)-2-indolinone

[0149] 3-(2-Ethoxybenzylidenyl)-2-indolinone is synthesized according to Method A.

5.37. Synthesis of 3-(4-Fluorobenzylidenyl)-2-indolinone

[0150] 3-(4-Fluorobenzylidenyl)-2-indolinone is synthesized according to Method A.

5.38. Synthesis of 3-[(Thien-2-yl)methylene]-2-indolinone

[0151] 3-[(Thien-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.39. Synthesis of 3-(2-Methoxybenzylidenyl)-2-indolinone

[0152] 3-(2-Methoxybenzylidenyl)-2-indolinone is synthesized according to Method A.

5.40. Synthesis of 3-[2-[3,5-Di-(trifluoromethyl)phenyl]furan-5-yl]methylene]-2-indolinone

[0153] 3-[2-[3,5-Di-(trifluoromethyl)phenyl]furan-5-yl]methylene]-2-indolinone is synthesized according to Method A.

5.41. Synthesis of 2,6-Di-(dimethylamino)-3,5-di-[(indolin-2-one-3-ylidenyl)methyl]-phenylcyanide

[0154] 2,6-Di-(dimethylamino)-3,5-di-[(indolin-2-one-3-ylidenyl)methyl]-phenylcyanide is synthesized according to Method A.

5.42. Synthesis of 3-[(3-(2-carboxyethyl)-4-methylpyrrol-5-yl)methylene]-2-indolinone

[0155] 3-[(3-(2-carboxyethyl)-4-methylpyrrol-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.43. Synthesis of 3-[(3,4-Dibromo-5-methylpyrrol-2-yl)methylene]-2-indolinone

[0156] 3-[(3,4-Dibromo-5-methylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method B.

5.44. Synthesis of 3-[(3,4-Dimethyl-2-formylpyrrole-5-yl)methylene]-2-indolinone

[0157] 3-[(3,4-Dimethyl-2-formylpyrrole-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.45. Synthesis of 3-[[4-(2-methoxycarbonylethyl)-3-methylpyrrol-5-yl]methylene]-2-indolinone

[0158] 3-[[4-(2-methoxycarbonylethyl)-3-methylpyrrol-5-yl]methylene]-2-indolinone is synthesized according to Method A.

EP 0 934 931 A2**5.46. Synthesis of 3-[2-Iodofuran-5-yl)methylene]-2-indolinone**

[0159] 3-[2-Iodofuran-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.47. Synthesis of 3-[(3-Ethoxycarbonyl-2-methylfuran-5-yl)methylene]-2-indolin one

[0160] 3-[(3-Ethoxycarbonyl-2-methylfuran-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.48. Synthesis of 3-[(3-Bromothiène-2-yl)methylene]-2-indolinone

[0161] 3-[(3-Bromothiène-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.49. Synthesis of 3-[(2-Chlorothiène-5-yl)methylene]-2-indolinone

[0162] 3-[(2-Chlorothiène-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.50. Synthesis of 3-[(2,3-Dimethylfuran-5-yl)methylene]-2-indolinone

[0163] 3-[(2,3-Dimethylfuran-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.51. Synthesis of 3-[(5-Nitrothien-2-yl)methylene]-2-indolinone

[0164] 3-[(5-Nitrothien-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.52. Synthesis of 3-[(2-Carboxythien-5-yl)methylene]-2-indolinone

[0165] 3-[(2-Carboxythien-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.53. Synthesis of 3-[(2-Bromothiène-5-yl)methylene]-2-indolinone

[0166] 3-[(2-Bromothiène-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.54. Synthesis of 3-[(4-Bromothiène-2-yl)methylene]-2-indolinone

[0167] 3-[(4-Bromothiène-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.55. Synthesis of 3-[(2-Sulphonylfuran-5-yl)methylene]-2-indolinone sodium salt

[0168] 3-[(2-Sulphonylfuran-5-yl)methylene]-2-indolinone sodium salt is synthesized according to Method A.

5.56. Synthesis of 3-[(Furan-2-yl)methylene]-2-Indolinone

[0169] 3-[(Furan-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.57. Synthesis of 3-[(2-Methylfuran-5-yl)methylene]-2-indolinone

[0170] 3-[(2-Methylfuran-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.58. Synthesis of 3-[(2-Ethylfuran-5-yl)methylene]-2-indolinone

[0171] 3-[(2-Ethylfuran-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.59. Synthesis of 3-[(2-Nitrofuran-5-yl)methylene]-2-indolinone

[0172] 3-[(2-Nitrofuran-5-yl)methylene]-2-indolinone is synthesized according to Method A.

EP 0 934 931 A2**5.60. Synthesis of 3-[(5-Bromofuran-2-yl)methylene]-2-indolinone**

[0173] 3-[(5-Bromofuran-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5 5.61. Synthesis of 3-[(2-Ethylthien-5-yl)methylene]-2-indolinone

[0174] 3-[(2-Ethylthien-5-yl)methylene]-2-indolinone is synthesized according to Method A.

10 5.62. Synthesis of 3-[(4,5-Dimethyl-3-ethylpyrrol-2-yl)methylene]-2-indolinone

[0175] 3-[(4,5-Dimethyl-3-ethylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

15 5.63. Synthesis of 3-[(5-Ethoxycarbonyl-4-ethoxycarbonyl-ethyl-3-ethoxycarbonylmethylpyrrol-2-yl)methylene]-2-indolinone

[0176] 3-[(5-Ethoxycarbonyl-4-ethoxycarbonyl-ethyl-3-ethoxycarbonylmethylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

20 5.64. Synthesis of 3-[(5-Carboxy-3-ethyl-4-methylpyrrol-2-yl)methylene]-2-indolinone

[0177] 3-[(5-Carboxy-3-ethyl-4-methylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

25 5.65. Synthesis of 3-[(3,5-Diiodo-4-methylpyrrol-2-yl)methylene]-2-indolinone

[0178] 3-[(3,5-Diiodo-4-methylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

30 5.66. Synthesis of 3-[(5-Chloro-3-methoxycarbonyl-4-methoxycarbonylmethylpyrrol-2-yl)methylene]-2-indolinone

[0179] 3-[(5-Chloro-3-methoxycarbonyl-4-methoxycarbonylmethylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

35 5.67. Synthesis of 3-[(3-Acetyl-5-ethoxycarbonyl-4-methylpyrrol-2-yl)methylene]-2-indolinone

[0180] 3-[(3-Acetyl-5-ethoxycarbonyl-4-methylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

40 5.68. Synthesis of 3-[[1-(3,5-Dichlorophenyl)pyrrol-2-yl]methylene]-2-indolinone

[0181] 3-[[1-(3,5-Dichlorophenyl)pyrrol-2-yl]methylene]-2-indolinone is synthesized according to Method A.

45 5.69. Synthesis of 3-[1-(4-Chlorophenyl)pyrrol-2-yl]methylene]-2-indolinone

[0182] 3-[1-(4-Chlorophenyl)pyrrol-2-yl]methylene]-2-indolinone is synthesized according to Method A.

50 5.70. Synthesis of 3-[(4-Ethoxycarbonyl-3-methyl)pyrrol-2-yl]methylene]-2-indolinone

[0183] 3-[(4-Ethoxycarbonyl-3-methyl)pyrrol-2-yl]methylene]-2-indolinone is synthesized according to Method A.

55 5.71. Synthesis of 3-[(1-Methylpyrrol-2-yl)methylene]-2-indolinone

[0184] 3-[(1-Methylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.72. Synthesis of 3-[(5-Ethoxycarbonyl-3-ethoxycarbonyl-ethyl-4-ethoxycarbonylmethylpyrrol-2-yl)methylene]-2-indolinone

[0185] 3-[(5-Ethoxycarbonyl-3-ethoxycarbonyl-ethyl-4-ethoxycarbonylmethylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

EP 0 934 931 A2**5.73. Synthesis of 3-[4-(Pyrrolidin-1-yl)benzylidenyl]-2-indolinone**

[0186] 3-[4-(Pyrrolidin-1-yl)benzylidenyl]-2-indolinone is synthesized according to Method A.

5.74. Synthesis of 3-[(5-Methylimidazol-2-yl)methylene]-2-indolinone

[0187] 3-[(5-Methylimidazol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.75. Synthesis of 3-[(5-Methylthiazol-2-yl)methylene]-2-indolinone

[0188] 3-[(5-Methylthiazol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.76. Synthesis of 3-[(3-Methylpyrazol-5-yl)methylene]-2-indolinone

[0189] 3-[(3-Methylpyrazol-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.77. Synthesis of 3-[(Imidazol-4-yl)methylene]-2-indolinone

[0190] 3-[(Imidazol-4-yl)methylene]-2-indolinone is synthesized according to Method A.

5.78. Synthesis of 3-[(4-Chloropyrazol-3-yl)methylene]-2-indolinone

[0191] 3-[(4-Chloropyrazol-3-yl)methylene]-2-indolinone is synthesized according to Method A.

5.79. Synthesis of 3-[(4-Bromo-1-(4-chlorobenzyl)pyrazol-5-yl)methylene]-2-indolinone

[0192] 3-[(4-Bromo-1-(4-chlorobenzyl)pyrazol-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.80. Synthesis of 3-[(4-Chloro-1-methylpyrazol-3-yl)methylene]-2-indolinone

[0193] 3-[(4-Chloro-1-methylpyrazol-3-yl)methylene]-2-indolinone is synthesized according to Method A.

5.81. Synthesis of 3-[(4-Ethyl-3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone

[0194] 3-[(4-Ethyl-3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method B.

5.82. Synthesis of 3-[(5-Ethylpyrrol-2-yl)methylene]-2-indolinone

[0195] 3-[(5-Ethylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method B.

5.83. Synthesis of 3-[3,5-Dimethyl-4-(propen-2-yl)pyrrol-2-yl)methylene]-2-indolinone

[0196] 3-[3,5-Dimethyl-4-(propen-2-yl)pyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method B.

5.84. Synthesis of 5,6-Dimethoxyl-3-[2,3-dimethoxybenzylidenyl]-2-indolinone

[0197] 5,6-Dimethoxyl-3-[2,3-dimethoxybenzylidenyl]-2-indolinone is synthesized according to Method A.

5.85. Synthesis of 3-[2,4,6-Trimethoxybenzylidenyl]-2-indolinone

[0198] 3-[2,4,6-Trimethoxybenzylidenyl]-2-indolinone is synthesized according to Method A.

5.86. Synthesis of 5-Chloro-3-[(pyrrol-2-yl)methylene]-2-indolinone

[0199] 5-Chloro-3-[(pyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

EP 0 934 931 A2**5.87. Synthesis of 5-Chloro-3-[(3-methylpyrrol-2-yl)methylene]-2-indolinone**

[0200] 5-Chloro-3-[(3-methylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5 5.88. Synthesis of 3-(4-isopropylbenzylidenyl)-2-indolinone

[0201] 3-(4-isopropylbenzylidenyl)-2-indolinone is available from Maybridge Chemical Co. Ltd.

5.89. Synthesis of 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone

10 [0202] 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.90. Synthesis of 3-[(pyrrol-2-yl)methylene]-2-indolinone

15 [0203] 3-[(pyrrol-2-yl)methylene]-2-indolinone is available from Maybridge Chemical Co. Ltd.

5.91. Synthesis of 5-Chloro-3-[(indol-3-yl)methylene]-2-indolinone

20 [0204] 5-Chloro-3-[(indol-3-yl)methylene]-2-indolinone is synthesized according to Method A.

5.92. Synthesis of 5-Chloro-3-[(thien-2-yl)methylene]-2-indolinone

[0205] 5-Chloro-3-[(thien-2-yl)methylene]-2-indolinone is synthesized according to Method A.

25 5.93. Synthesis of 5-Chloro-3-[(3-methylthien-2-yl)methylene]-2-indolinone

[0206] 5-Chloro-3-[(3-methylthien-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.94. Synthesis of 5-Chloro-3-[(5-methylthien-2-yl)methylene]-2-indolinone

30 [0207] 5-Chloro-3-[(5-methylthien-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.95. Synthesis of 5-Chloro-3-[(5-ethylthien-2-yl)methylene]-2-indolinone

35 [0208] 5-Chloro-3-[(5-ethylthien-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.96. Synthesis of 5-Chloro-3-[(5-methylmercaptothien-2-yl)methylene]-2-indolinone

40 [0209] 5-Chloro-3-[(5-methylmercaptothien-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.97. Synthesis of 5-chloro-3-[(imidazol-2-yl)methylene]-2-indolinone

[0210] 5-Chloro-3-[(imidazol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

45 5.98. Synthesis of 3-[2,4-Dimethoxy-6-methylbenzylidenyl]-2-indolinone

[0211] 3-[2,4-Dimethoxy-6-methylbenzylidenyl]-2-indolinone is synthesized according to Method A.

5.99. Synthesis of 5-Nitro-3-[(pyrrol-2-yl)methylene]-2-indolinone

50 [0212] 5-Nitro-3-[(pyrrol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.100. Synthesis of 3-[(3-Methylpyrrol-2-yl)methylene]-5-nitro-2-indolinone

55 [0213] 3-[(3-Methylpyrrol-2-yl)methylene]-5-nitro-2-indolinone is synthesized according to Method A.

EP 0 934 931 A2**5.101. Synthesis of 3-[(3,5-Dimethylpyrrol-2-yl)methylene]-5-nitro-2-indolinone**

[0214] 3-[(3,5-Dimethylpyrrol-2-yl)methylene]-5-nitro-2-indolinone is synthesized according to Method A.

5.102. Synthesis of 3-[(Indol-3-yl)methylene]-5-nitro-2-indolinone

[0215] 3-[(Indol-3-yl)methylene]-5-nitro-2-indolinone is synthesized according to Method A.

5.103. Synthesis of 5-Nitro-3-[(thien-2-yl)methylene]-2-indolinone

[0216] 5-Nitro-3-[(thien-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.104. Synthesis of 3-[(3-Methylthien-2-yl)methylene]-5-nitro-2-indolinone

[0217] 3-[(3-Methylthien-2-yl)methylene]-5-nitro-2-indolinone is synthesized according to Method A.

5.105. Synthesis of 3-[(5-Methylthien-2-yl)methylene]-5-nitro-2-indolinone

[0218] 3-[(5-Methylthien-2-yl)methylene]-5-nitro-2-indolinone is synthesized according to Method A.

5.106. Synthesis of 3-[(5-Ethylthien-2-yl)methylene]-5-nitro-2-indolinone

[0219] 3-[(5-Ethylthien-2-yl)methylene]-5-nitro-2-indolinone is synthesized according to Method A.

5.107. Synthesis of 3-[(5-Methylmercaptothien-2-yl)methylene]-5-nitro-2-indolinone

[0220] 3-[(5-Methylmercaptothien-2-yl)methylene]-5-nitro-2-indolinone is synthesized according to Method A.

5.108. Synthesis of 3-[(Imidazol-2-yl)methylene]-5-nitro-2-indolinone

[0221] 3-[(Imidazol-2-yl)methylene]-5-nitro-2-indolinone is synthesized according to Method A.

5.109. Synthesis of 3-[(Oxazol-2-yl)methylene]-2-indolinone

[0222] 3-[(Oxazol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.110. Synthesis of 3-[(Oxazol-4-yl)methylene]-2-indolinone

[0223] 3-[(Oxazol-4-yl)methylene]-2-indolinone is synthesized according to Method A.

5.111. Synthesis of 3-[(Oxazol-5-yl)methylene]-2-indolinone

[0224] 3-[(Oxazol-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.112. Synthesis of 3-[(Thiazol-2-yl)methylene]-2-indolinone

[0225] 3-[(Thiazol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5.113. Synthesis of 3-[(Thiazol-4-yl)methylene]-2-indolinone

[0226] 3-[(Thiazol-4-yl)methylene]-2-indolinone is synthesized according to Method A.

5.114. Synthesis of 3-[(Thiazol-5-yl)methylene]-2-indolinone

[0227] 3-[(Thiazol-5-yl)methylene]-2-indolinone is synthesized according to Method A.

EP 0 934 931 A2**5.115. Synthesis of 3-[(Imidazol-2-yl)methylene]-2-indolinone**

[0228] 3-[(Imidazol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

5 5.116. Synthesis of 3-[(Pyrazol-3-yl)methylene]-2-indolinone

[0229] 3-[(Pyrazol-3-yl)methylene]-2-indolinone is synthesized according to Method A.

5.117. Synthesis of 3-[(Pyrazol-4-yl)methylene]-2-indolinone

10 [0230] 3-[(Pyrazol-4-yl)methylene]-2-indolinone is synthesized according to Method A.

5.118. Synthesis of 3-[(Isoxazol-3-yl)methylene]-2-indolinone

15 [0231] 3-[(Isoxazol-3-yl)methylene]-2-indolinone is synthesized according to Method A.

5.119. Synthesis of 3-[(Isoxazol-4-yl)methylene]-2-indolinone

20 [0232] 3-[(Isoxazol-4-yl)methylene]-2-indolinone is synthesized according to Method A.

5.120. Synthesis of 3-[(Isoxazol-5-yl)methylene]-2-indolinone

[0233] 3-[(Isoxazol-5-yl)methylene]-2-indolinone is synthesized according to Method A.

25 5.121. Synthesis of 3-[(Isothiazol-3-yl)methylene]-2-indolinone

[0234] 3-[(Isothiazol-3-yl)methylene]-2-indolinone is synthesized according to Method A.

5.122. Synthesis of 3-[(Isothiazol-4-yl)methylene]-2-indolinone

30 [0235] 3-[(Isothiazol-4-yl)methylene]-2-indolinone is synthesized according to Method A.

5.123. Synthesis of 3-[(Isothiazol-5-yl)methylene]-2-indolinone

35 [0236] 3-[(Isothiazol-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.124. Synthesis of 3-[(1,2,3-Triazol-4-yl)methylene]-2-indolinone

40 [0237] 3-[(1,2,3-Triazol-4-yl)methylene]-2-indolinone is synthesized according to Method A.

5.125. Synthesis of 3-[(1,3,4-Thiadiazol-2-yl)methylene]-2-indolinone

[0238] 3-[(1,3,4-Thiadiazol-2-yl)methylene]-2-indolinone is synthesized according to Method A.

45 5.126. Synthesis of 3-[(5-Phenyl-1,2,4-oxadiazol-3-yl)methylene]-2-indolinone

[0239] 3-[(5-Phenyl-1,2,4-oxadiazol-3-yl)methylene]-2-indolinone is synthesized according to Method A.

5.127. Synthesis of 3-[(3-Phenyl-1,2,4-oxadiazol-5-yl)methylene]-2-indolinone

50 [0240] 3-[(3-Phenyl-1,2,4-oxadiazol-5-yl)methylene]-2-indolinone is synthesized according to Method A.

5.128. Synthesis of 3-[(3-Phenyl-1,2,5-oxadiazol-4-yl)methylene]-2-indolinone

55 [0241] 3-[(3-Phenyl-1,2,5-oxadiazol-4-yl)methylene]-2-indolinone is synthesized according to Method A.

EP 0 934 931 A2

6. EXAMPLES: *In Vitro* RTK Assays

[0242] The following *in vitro* assays may be used to determine the level of activity and effect of the different compounds of the present invention on one or more of the RTKs. Similar assays can be designed along the same lines for any tyrosine kinase using techniques well known in the art.

6.1. Enzyme Linked Immunosorbent Assay (ELISA)

[0243] Enzyme linked immunosorbent assays (ELISA) may be used to detect and measure the presence of tyrosine kinase activity. The ELISA may be conducted according to known protocols which are described in, for example, Voller, *et al.*, 1980, "Enzyme-Linked Immunosorbent Assay," In: *Manual of Clinical Immunology*, 2d ed., edited by Rose and Friedman, pp 359-371 Am. Soc. Of Microbiology, Washington, D.C.

[0244] The disclosed protocol may be adapted for determining activity with respect to a specific RTK. For example, the preferred protocols for conducting the ELISA experiments for specific RTKs is provided below. Adaptation of these protocols for determining a compound's activity for other members of the RTK family, as well as non-receptor tyrosine kinases, are within the scope of those in the art.

6.1.1. FLK-1 ELISA

[0245] An ELISA assay was conducted to measure the kinase activity of the FLK-1 receptor and more specifically, the inhibition or activation of protein tyrosine kinase activity on the FLK-1 receptor. Specifically, the following assay was conducted to measure kinase activity of the FLK-1 receptor in FLK-1/NIH3T3 cells.

Materials And Methods.

[0246] *Materials.* The following reagents and supplies were used:

- a. Corning 96-well ELISA plates (Corning Catalog No. 25805-96);
- b. Cappel goat anti-rabbit IgG (catalog no. 55641);
- c. PBS (Gibco Catalog No. 450-1300EB);
- d. TBSW Buffer (50 mM Tris (pH 7.2), 150 mM NaCl and 0.1% Tween-20);
- e. Ethanolamine stock (10% ethanolamine (pH 7.0), stored at 4°C);
- f. HNTG buffer (20mM HEPES buffer (pH 7.5), 150mM NaCl, 0.2% Triton X-100, and 10% glycerol);
- g. EDTA (0.5 M (pH 7.0) as a 100X stock);
- h. Sodium ortho vanadate (0.5 M as a 100X stock);
- i. Sodium pyro phosphate (0.2M as a 100X stock);
- j. NUNC 96 well V bottom polypropylene plates (Applied Scientific Catalog No. AS-72092);
- k. NIH3T3 C7#3 Cells (FLK-1 expressing cells);
- l. DMEM with 1X high glucose L Glutamine (catalog No. 11965-050);
- m. FBS, Gibco (catalog no. 16000-028);
- n. L-glutamine, Gibco (catalog no. 25030-016);
- o. VEGF, PeproTech, Inc. (catalog no. 100-20) (kept as 1 µg/100 µl stock in Milli-Q dH₂O and stored at -20°C;
- p. Affinity purified anti-FLK-1 antiserum, Enzymology Lab, Sugan, Inc.;
- q. UB40 monoclonal antibody specific for phosphotyrosine, Enzymology Lab, Sugan, Inc. (see, Fendley, *et al.*, 1990, *Cancer Research* 50:1550-1558);
- r. EIA grade Goat anti-mouse IgG-POD (BioRad catalog no. 172-1011);
- s. 2,2-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid (ABTS) solution (100mM citric acid (anhydrous), 250 mM Na₂HPO₄ (pH 4.0), 0.5 mg/ml ABTS (Sigma catalog no. A-1888)), solution should be stored in dark at 4°C until ready for use;
- t. H₂O₂ (30% solution) (Fisher catalog no. H325);
- u. ABTS/H₂O₂ (15ml ABTS solution, 2 µl H₂O₂) prepared 5 minutes before use and left at room temperature;
- v. 0.2 M HCl stock in H₂O;
- w. dimethylsulfoxide (100%) (Sigma Catalog No. D-8418); and
- y. Trypsin-EDTA (Gibco BRL Catalog No. 25200-049).

[0247] *Protocol.* The following protocol was used for conducting the assay:

1. Coat Corning 96-well elisa plates with 1.0µg per well Cappel Anti-rabbit IgG antibody in 0.1M Na₂CO₃ pH 9.6.

EP 0 934 931 A2

Bring final volume to 150 μ l per well. Coat plates overnight at 4°C. Plates can be kept up to two weeks when stored at 4°C.

2. Grow cells in Growth media(DMEM, supplemental with 2.0mM L-Glutamine, 10% FBS) in suitable culture dishes until confluent at 37°C, 5% CO₂.

3. Harvest cells by trypsinization and seed in Corning 25850 polystyrene 96-well roundbottom cell plates, 25,000 cells/well in 200 μ l of growth media.

4. Grow cells at least one day at 37°C, 5% CO₂.

5. Wash cells with D-PBS 1X.

6. Add 200 μ l/well of starvation media (DMEM, 2.0mM L-Glutamine, 0.1% FBS). Incubate overnight at 37°C, 5% CO₂.

7. Dilute Compounds/Extracts 1:20 in polypropylene 96 well plates using starvation media. Dilute dimethylsulfoxide 1:20 for use in control wells.

8. Remove starvation media from 96 well cell culture plates and add 162 μ l of fresh starvation media to each well.

9. Add 18 μ l of 1:20 diluted Compound/Extract dilution (from step 7) to each well plus the 1:20 dimethylsulfoxide dilution to the control wells (+/- VEGF), for a final dilution of 1:200 after cell stimulation. Final dimethylsulfoxide is 0.5 %.

10. Incubate the plate at 37°C, 5% CO₂ for two hours.

11. Remove unbound antibody from ELISA plates by inverting plate to remove liquid. Wash 3 times with TBSW + 0.5% ethanolamine, pH 7.0. Pat the plate on a paper towel to remove excess liquid and bubbles.

12. Block plates with TBSW + 0.5% Ethanolamine, pH 7.0, 150 μ l per well. Incubate plate thirty minutes while shaking on a microtiter plate shaker.

13. Wash plate 3 times as described in step 10.

14. Add 0.5 μ g/well affinity purified anti-FLU-1 polyclonal rabbit antiserum. Bring final volume to 150 μ l/well with TBSW + 0.5% ethanolamine pH 7.0. Incubate plate for thirty minutes while shaking.

15. Add 180 μ l starvation medium to the cells and stimulate cells with 20 μ l/well 10.0mM sodium ortho vanadate and 500 ng/ml VEGF (resulting in a final concentration of 1.0mM sodium ortho vanadate and 50ng/ml VEGF per well) for eight minutes at 37°C, 5% CO₂. Negative control wells receive only starvation medium.

16. After eight minutes, media should be removed from the cells and washed one time with 200 μ l/well PBS.

17. Lyse cells in 150 μ l/well HNTG while shaking at room temperature for five minutes. HNTG formulation includes sodium ortho vanadate, sodium pyro phosphate and EDTA.

18. Wash ELISA plate three times as described in step 10.

19. Transfer cell lysates from the cell plate to elisa plate and incubate while shaking for two hours. To transfer cell lysate pipette up and down while scrapping the wells.

20. Wash plate three times as described in step 10.

21. Incubate ELISA plate with 0.02 μ g/well UB40 in TBSW + 05% ethanolamine. Bring final volume to 150 μ l/well. Incubate while shaking for 30 minutes.

22. Wash plate three times as described in step 10.

23. Incubate ELISA plate with 1:10,000 diluted EIA grade goat anti-mouse IgG conjugated horseradish peroxidase in TBSW + 0.5% ethanolamine, pH 7.0. Bring final volume to 150 μ l/well. Incubate while shaking for thirty minutes.

24. Wash plate as described in step 10.

25. Add 100 μ l of ABTS/H₂O₂ solution to well. Incubate ten minutes while shaking.

26. Add 100 μ l of 0.2 M HCl for 0.1 M HCl final to stop the color development reaction. Shake 1 minute at room temperature. Remove bubbles with slow streak of air and read the ELISA plate in an ELISA plate reader at 410 nm.

6.1.2. HER-2 ELISA

[0248] Assay 1: EGF Receptor-HER2 Chimeric Receptor Assay In Whole Cells. HER2 kinase activity in whole EGFR-NIH3T3 cells was measured as described below:

[0249] **Materials and Reagents.** The following materials and reagents were used to conduct the assay:

a. EGF: stock concentration= 16.5 ILM; EGF 201, TOYOKO, Co., Ltd. Japan.

b. 05-101 (UBI) (a monoclonal antibody recognizing an EGFR extracellular domain).

c. Anti-phosphotyrosine antibody (anti-Ptyr) (polyclonal)(see, Fendley, *et al.*, *supra*).

d. Detection antibody: Goat anti-rabbit IgG horse radish peroxidase conjugate, TAGO, Inc., Burlingame, CA.

e. TBST buffer:

EP 0 934 931 A2

5

Tris-HCl, pH 7.2	50 mM
NaCl	150 mM
Triton X-100	0.1

10

f. HNTG 5X stock:

15

HEPES	0.1 M
NaCl	0.75 M
Glycerol	50%
Triton X-100	1.0%

20

g. ABTS stock:

25

Citric Acid	100 mM
Na ₂ HPO ₄	250 mM
HCl, conc.	0.5 pM
ABTS*	0.5mg/ml

30

* (2,2' -azinobis(3-ethyl-benzthiazolinesulfonic acid)). Keep solution in dark at 4°C until use.

35

h. Stock reagents of:

40

EDTA 100 mM pH 7.0
Na₃VO₄ 0.5 M
Na₄(P₂O₇) 0.2 M

[0250] **Procedure.** The following protocol was used:

45

A. Pre-coat ELISA Plate

[0251]

50

1. Coat ELISA plates (Corning, 96 well, Cat. #25805-96) with 05-101 antibody at 0.5 g per well in PBS, 100 µl final volume/well, and store overnight at 4°C. Coated plates are good for up to 10 days when stored at 4°C.
2. On day of use, remove coating buffer and replace with 100 µl blocking buffer (5% Carnation Instant Non-Fat Dry Milk in PBS). Incubate the plate, shaking, at room temperature (about 23°C to 25°C) for 30 minutes. Just prior to use, remove blocking buffer and wash plate 4 times with TBST buffer.

55

EP 0 934 931 A2

B. Seeding Cells

[0252]

1. An NIH3T3 cell line overexpressing a chimeric receptor containing the EGFR extracellular domain and extracellular HER2 kinase domain can be used for this assay.
2. Choose dishes having 80-90% confluence for the experiment. Trypsinize cells and stop reaction by adding 10% fetal bovine serum. Suspend cells in DMEM medium (10% CS DMEM medium) and centrifuge once at 1500 rpm, at room temperature for 5 minutes.
3. Resuspend cells in seeding medium (DMEM, 0.5% bovine serum), and count the cells using trypan blue. Viability above 90% is acceptable. Seed cells in DMEM medium (0.5% bovine serum) at a density of 10,000 cells per well, 100 μ l per well, in a 96 well microtiter plate. Incubate seeded cells in 5% CO₂ at 37°C for about 40 hours.

C. Assay Procedures

[0253]

1. Check seeded cells for contamination using an inverted microscope. Dilute drug stock (10 mg/ml in DMSO) 1:10 in DMEM medium, then transfer 5 l to a TBST well for a final drug dilution of 1:200 and a final DMSO concentration of 1%. Control wells receive DMSO alone. Incubate in 5% CO₂ at 37°C for two hours.
2. Prepare EGF ligand: dilute stock EGF in DMEM so that upon transfer of 10 μ l dilute EGF (1:12 dilution), 100 nM final concentration is attained.
3. Prepare fresh HNTG* sufficient for 100 μ l per well; and place on ice.

HNTG* (10 ml):	
HNTG stock	2.0 ml
milli-Q H ₂ O	7.3 ml
EDTA, 100 mM, pH 7.0	0.5 ml
Na ₃ VO ₄ , 0.5 M	0.1 ml
Na ₄ (P ₂ O ₇), 0.2 M	0.1 ml

4. After 120 minutes incubation with drug, add prepared SGF ligand to cells, 10 μ l per well, to a final concentration of 100 nM. Control wells receive DMEM alone. Incubate, shaking, at room temperature, for 5 minutes.
5. Remove drug, EGF, and DMEM. Wash cells twice with PBS. Transfer HNTG* to cells, 100 μ l per well. Place on ice for 5 minutes. Meanwhile, remove blocking buffer from other ELISA plate and wash with TBST as described above.
6. With a pipette tip securely fitted to a micropipettor, scrape cells from plate and homogenize cell material by repeatedly aspirating and dispensing the HNTG* lysis buffer. Transfer lysate to a coated, blocked, and washed ELISA plate. Incubate shaking at room temperature for one hour.
7. Remove lysate and wash 4 times with TBST. Transfer freshly diluted anti-Ptyr antibody to ELISA plate at 100 μ l per well. Incubate shaking at room temperature for 30 minutes in the presence of the anti-Ptyr antiserum (1:3000 dilution in TBST).
8. Remove the anti-Ptyr antibody and wash 4 times with TBST. Transfer the freshly diluted TAGO anti-rabbit IgG antibody to the ELISA plate at 100 μ l per well. Incubate shaking at room temperature for 30 minutes (anti-rabbit IgG antibody: 1:3000 dilution in TBST).
9. Remove TAGO detection antibody and wash 4 times with TBST. Transfer freshly prepared ABTS/H₂O₂ solution to ELISA plate, 100 μ l per well. Incubate shaking at room temperature for 20 minutes. (ABTS/H₂O₂ solution: 1.0 ml 30% H₂O₂ in 10 ml ABTS stock).
10. Stop reaction by adding 50 μ l 5N H₂SO₄ (optional), and determine O.D. at 410 nm.
11. The maximal phosphotyrosine signal is determined by subtracting the value of the negative controls from the positive controls. The percent inhibition of phosphotyrosine content for extract-containing wells is then calculated, after subtraction of the negative controls.

EP 0 934 931 A2

[0254] Assay 2: HER-2-BT474 ELISA. A second assay may be conducted to measure whole cell HER2 activity. Such assay may be conducted as follows:

[0255] Materials And Reagents. The following materials and reagents were used:

- a. BT-474 (ATCC HBT20), a human breast tumor cell line which expresses high levels of HER2 kinase.
- b. Growth media comprising RPMI + 10% FBS + GMS-G (Gibco supplement) + glutamine for use in growing BT-474 in an incubator with 5% CO₂ at 37°C.
- c. A monoclonal anti-HER2 antibody.
- d. D-PBS:

KH ₂ HPO ₄	0.20 g/l 10 (GIBCO,310-4190AJ)
K ₂ HPO ₄	2.16 g/l
KCl	0.20 g/l
NaCl	8.00 g/l (pH 7.2)

- e. Blocking Buffer: TBST plus 5% Milk (Carnation Instant Non-Fat Dry Milk).
- f. TBST buffer:

Tris-HCl	50 mM
NaCl	150 mM (pH 7.2, HCl 10 N)
Triton X-100	0.1%

wherein stock solution of TES (10X) is prepared, and Triton X-100 is added to the buffer during dilution.

g. HNTG buffer (5x):

HEPES	0.1 M
NaCl	750 mM (pH 7.2 (HCl, 1 N)
Glycerol	50%
Triton X-100	1.0%

Stock solution (5x) is prepared and kept in 4°C.

h. EDTA-HCl: 0.5 M pH 7.0 (10 N HCl) as 500X stock.

i. Na₃VO₄: 0.5 M as 100X stock is kept at -80°C as aliquots.

j. Na₄(P₂O₇): 0.2 M as 100X stock.

k. Polyclonal antiserum anti-phosphotyrosine.

l. Goat anti-rabbit IgG, horseradish peroxidase (POD) conjugate (detection antibody), Tago (Cat. No. 4520; Lot No. 1802); Tago, Inc., Burlingame, CA.

m. ABTS solution:

Citric acid	100 mM
Na ₂ HPO ₄	250 mM (pH 4.0, 1 N HCl)
ABTS	0.5 mg/ml

EP 0 934 931 A2

wherein ABTS is 2,2'-azino-bis(3-ethylbenzthiazoline sulfonic acid). For this assay, the ABTS solution should be kept in the dark at 4°C. The solution should be discarded when it turns green.

n. Hydrogen peroxide: 30% solution is kept in dark and 4°C.

- 5 [0256] **Procedure.** All the following steps are at room temperature and aseptically, unless stated otherwise. All ELISA plate washing is by rinsing with distilled water three times and once with TBST.

A. Cell Seeding

10 [0257]

1. Grow BT474 cells in tissue culture dishes (Corning 25020-100) to 80-90% confluence and collect using Trypsin-EDTA (0.25%, GIBCO).
2. Resuspend the cells in fresh medium and transfer to 96-well tissue culture plates (Corning, 25806-96) at about 25,000-50,000 cells/well (100 µl/well). Incubate the cells in 5% CO₂ at 37°C overnight.

B. ELISA Plate Coating and Blocking

[0258]

20

1. Coat the ELISA plate (Corning 25805-96) with anti HER2 antibody at 0.5 µg/well in 150 µl PBS overnight at 4°C, and seal with parafilm. The antibody coated plates can be used up to 2 weeks, when stored at 4°C.
2. On the day of use, remove the coating solution, replace with 200 µl of Blocking Buffer, shake the plate, and then remove the blocking buffer and wash the plate just before adding lysate.

25

C. Assay Procedures

[0259]

30

1. TBST the drugs in serum-free condition. Before adding drugs, the old media is replaced with serum-free RPMI (90 µl/well)
2. Dilute drug stock (in 100% DMSO) 1:10 with RPMI, and transfer 10 µl/well of this solution to the cells to achieve a final drug DMSO concentration at 1%. Incubate the cells in 5% CO₂ at 37°C.
3. Prepare fresh cell lysis buffer (HNTG*)

35

5xHNTG	2 ml
EDTA	0.2 ml
Na ₃ VO ₄	0.1 ml
Na ₄ P ₂ O ₇	0.1 ml
H ₂ O	7.3 ml

40

45

4. After drug preincubation for two hours remove all the solution from the plate, transfer HNTG* (100 µl/well) to the cells, and shake for 10 minutes.
5. Use a 12-channel pipette to scrape the cells from the plate, and homogenize the lysate by repeat aspiration and dispensing. Transfer all the lysate to the ELISA plate and shake for 1 hour.
6. Remove the lysate, wash the plate, add anti-pTyr (1:3,000 with TBST) 100 µl/well, and shake for 30 minutes.
7. Remove anti-pTyr, wash the plate, add goat anti-rabbit IgG conjugated antibody (1:5,000 with TBST) 100 µl/well, and shake for 30 minutes.
8. Remove anti-rabbit IgG antibody, wash the plate, and add fresh ABTS/H₂O₂ (1.2 µl H₂O₂ to 10 ml ABTS) 100 µl/well to the plate to start color development, which usually takes 20 minutes.
9. Measure OD 410 nm, Dynatec MR5000.

55

EP 0 934 931 A2

6.1.3. PDGF-R ELISA

[0260] All cell culture media, glutamine, and fetal bovine serum were purchased from Gibco Life Technologies (Grand Island, NY) unless otherwise specified. All cells were grown in a humid atmosphere of 90-95% air and 5-10% CO₂ at 37°C. All cell lines were routinely subcultured twice a week and were negative for mycoplasma as determined by the Mycotect method (Gibco).

[0261] For ELISA assays, cells (U1242, obtained from Joseph Schlessinger, NYU) were grown to 80-90% confluency in growth medium (MEM with 10% FBS, NEAA, 1 mM NaPyr and 2 mM GLN) and seeded in 96-well tissue culture plates in 0.5% serum at 25,000 to 30,000 cells per well. After overnight incubation in 0.5% serum-containing medium, cells were changed to serum-free medium and treated with test compound for 2 hr in a 5% CO₂, 37°C incubator. Cells were then stimulated with ligand for 5-10 minute followed by lysis with HNTG (20 mM Hepes, 150 mM NaCl, 10% glycerol, 5 mM EDTA, 5 mM Na₃VO₄, 0.2% Triton X-100, and 2 mM NaPyr). Cell lysates (0.5 mg/well in PBS) were transferred to ELISA plates previously coated with receptor-specific antibody and which had been blocked with 5% milk in TBST (50 mM Tris-HCl pH 7.2, 150 mM NaCl and 0.1% Triton X-100) at room temperature for 30 min. Lysates were incubated with shaking for 1 hour at room temperature. The plates were washed with TBST four times and then incubated with polyclonal anti-phosphotyrosine antibody at room temperature for 30 minutes. Excess anti-phosphotyrosine antibody was removed by rinsing the plate with TBST four times. Goat anti-rabbit IgG antibody was added to the ELISA plate for 30 min at room temperature followed by rinsing with TBST four more times. ABTS (100 mM citric acid, 250 mM Na₂HPO₄ and 0.5 mg/mL 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)) plus H₂O₂ (1.2 mL 30% H₂O₂ to 10 ml ABTS) was added to the ELISA plates to start color development. Absorbance at 410 nm with a reference wavelength of 630 nm was recorded about 15 to 30 min after ABTS addition.

6.1.4. IGF-I ELISA

[0262] The following protocol may be used to measure phosphotyrosine level on IGF-I receptor, which indicates IGF-I receptor tyrosine kinase activity.

[0263] **Materials and Reagents.** The following materials and reagents were used:

- a. The cell line used in this assay is 3T3/IGF-1R, a cell line which overexpresses IGF-1 receptor.
- b. NIH3T3/IGF-1R is grown in an incubator with 5% CO₂ at 37°C. The growth media is DMEM + 10% FBS (heat inactivated) + 2mM L-glutamine.
- c. Anti-IGF-1R antibody named 17-69 is used. Antibodies are purified by the Enzymology Lab, SUGEN, Inc.
- d. D-PBS:

KH ₂ PO ₄	0.20 g/l
K ₂ HPO ₄	2.16 g/l
KCl	0.20 g/l
NaCl	8.00 g/l (pH 7.2)

- e. Blocking Buffer: TBST plus 5% Milk (Carnation Instant Non-Fat Dry Milk).

- f. TBST buffer:

Tris-HCl	50 mM
NaCl	150mM (pH 7.2/HCl 10N)
Triton X-100	0.1%

- g. HNTG buffer:

Stock solution of TBS (10X) is prepared, and Triton X-100 is added to the buffer during dilution.

EP 0 934 931 A2

HEPES	20 mM
NaCl	150 mM (pH 7.2/HCl 1N)
Glycerol	10%
Triton X-100	0.2%

Stock solution (5X) is prepared and kept at 4°C.

h. EDTA/HCl: 0.5 M pH 7.0 (NaOH) as 100X stock.

i. Na_3VO_4 : 0.5 M as 100X stock and aliquots are kept in -80°C.

j. $\text{Na}_4\text{P}_2\text{O}_7$: 0.2 M as 100X stock.

k. Insulin-like growth factor-1 from Promega (Cat# G5111).

l. Polyclonal antiserum anti-phosphotyrosine: rabbit sera generated by Enzymology Lab., SUGEN Inc.

m. Goat anti-rabbit IgG, POD conjugate (detection antibody), Tago (Cat. No. 4520, Lot No. 1802): Tago, Inc., Burlingame, CA.

n. ABTS (2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid)) solution:

Citric acid	100 mM
Na_2HPO_4	250 mM (pH 4.0/1 N HCl)
ABTS	0.5 mg/ml

ABTS solution should be kept in dark and 4°C. The solution should be discarded when it turns green.

o. Hydrogen Peroxide: 30% solution is kept in the dark and at 4°C.

[0264] Procedure. All the following steps are conducted at room temperature unless it is specifically indicated. All ELISA plate washings are performed by rinsing the plate with tap water three times, followed by one TBST rinse. Pat plate dry with paper towels.

A. Cell Seeding:

[0265]

1. The cells, grown in tissue culture dish (Corning 25020-100) to 80-90% confluence, are harvested with Trypsin-EDTA (0.25%, 0.5 ml/D-100, GIBCO).

2. Resuspend the cells in fresh DMEM + 10% FBS + 2mM L-Glutamine, and transfer to 96 - well tissue culture plate (Corning, 25806-96) at 20,000 cells/well (100 μl /well). Incubate for 1 day then replace medium to serum-free medium (90/ μl) and incubate in 5% CO_2 and 37°C overnight.

B. ELISA Plate Coating and Blocking:

[0266]

1. Coat the ELISA plate (Corning 25805-96) with Anti-IGF-1R Antibody at 0.5 μg /well in 100 μl PBS at least 2 hours.

2. Remove the coating solution, and replace with 100 μl Blocking Buffer, and shake for 30 minutes. Remove the blocking buffer and wash the plate just before adding lysate.

C. Assay Procedures:

[0267]

1. The drugs are tested in serum-free condition.

EP 0 934 931 A2

2. Dilute drug stock (in 100% DMSO) 1:10 with DMEM in 96-well poly-propylene plate, and transfer 10 μ l/well of this solution to the cells to achieve final drug dilution 1:100, and final DMSO concentration of 1.0%. Incubate the cells in 5% CO₂ at 37°C for 2 hours.

3. Prepare fresh cell lysis buffer (HNTG*)

HNTG	2 ml
EDTA	0.1 ml
Na ₃ VO ₄	0.1 ml
Na ₄ (P ₂ O ₇)	0.1 ml
H ₂ O	7.3 ml

4. After drug incubation for two hours, transfer 10 μ l/well of 200nM IGF-1 Ligand in PBS to the cells (Final Conc. = 20 nM), and incubate at 5% CO₂ at 37°C for 10 minutes.

5. Remove media and add 100 μ l/well HNTG* and shake for 10 minutes. Look at cells under microscope to see if they are adequately lysed.

6. Use a 12-channel pipette to scrape the cells from the plate, and homogenize the lysate by repeat aspiration and dispense. Transfer all the lysate to the antibody coated ELISA plate, and shake for 1 hour.

7. Remove the lysate, wash the plate, transfer anti-pTyr (1:3,000 with TBST) 100 μ l/well, and shake for 30 minutes.

8. Remove anti-pTyr, wash the plate, transfer Tago (1:3,000 with TBST) 100 μ l/well, and shake for 30 minutes.

9. Remove detection antibody, wash the plate, and transfer fresh ABTS/H₂O₂ (1.2 μ l H₂O₂ to 10 ml ABTS) 100 μ l/well to the plate to start color development.

10. Measure OD in Dynatec MR5000, which is connected to Ingres.

6.1.5. EGF Receptor ELISA

[0268] EGF Receptor kinase activity (EGFR-NIH3T3 assay) in whole cells was measured as described below:

[0269] **Materials and Reagents.** The following materials and reagents were used

a. EGF Ligand: stock concentration = 16.5 μ M; EGF 201, TOYOBO, Co., Ltd. Japan.

b. 05-101 (UBI) (a monoclonal antibody recognizing an EGFR extracellular domain).

c. Anti-phosphotyrosine antibody (anti-Ptyr) (polyclonal).

d. Detection antibody: Goat anti-rabbit IgG horse radish peroxidase conjugate, TAGO, Inc., Burlingame, CA.

e. TBST buffer.

Tris-HCl, pH 7	50 mM
NaCl	150 mM
Triton X-100	0.1

f. HNTG 5X stock:

HEPES	0.1 M
NaCl	0.75 M
Glycerol	50
Triton X-100	1.0%

EP 0 934 931 A2

g. ABTS stock:

5	Citric Acid	100 mM
	Na ₂ HPO ₄	250 mM
	HCl, conc.	4.0 pH
10	ABTS*	0.5 mg/ml

Keep solution in dark at 4°C until used.

h. Stock reagents of:

- 15 EDTA 100 mM pH 7.0
Na₃VO₄ 0.5 M
Na₄(P₂O₇) 0.2 M

[0270] **Procedure.** The following protocol was used:

20

A. Pre-coat ELISA Plate

[0271]

- 25 1. Coat ELISA plates (Corning, 96 well, Cat. #25805-96) with 05-101 antibody at 0.5 µg per well in PBS, 150 µl final volume/well, and store overnight at 4°C. Coated plates are good for up to 10 days when stored at 4°C.
2. On day of use, remove coating buffer and replace with blocking buffer (5% Carnation Instant NonFat Dry Milk in PBS). Incubate the plate, shaking, at room temperature (about 23°C to 25°C) for 30 minutes. Just prior to use, remove blocking buffer and wash plate 4 times with TBST buffer.

30

B. Seeding Cells

[0272]

- 35 1. NIH 3T3/C7 cell line (Honegger, et al., Cell 51:199-209, 1987) can be use for this assay.
2. Choose dishes having 80-90% confluence for the experiment. Trypsinize cells and stop reaction by adding 10% CS DMEM medium. Suspend cells in DMEM medium (10% CS DMEM medium) and centrifuge once at 1000 rpm, and once at room temperature for 5 minutes.
3. Resuspend cells in seeding medium (DMEM, 0.5% bovine serum), and count the cells using trypan blue. Viability
40 above 90% is acceptable. Seed cells in DMEM medium (0.5% bovine serum) at a density of 10,000 cells per well, 100 µl per well, in a 96 well microtiter plate. Incubate seeded cells in 5% CO₂ at 37°C for about 40 hours.

C. Assay Procedures.

45 [0273]

1. Check seeded cells for contamination using an inverted microscope. Dilute drug stock (10 mg/ml in DMSO) 1:10 in DMEM medium, then transfer 5 µl to a test well for a final drug dilution of 1:200 and a final DMSO concentration of 1%. Control wells receive DMSO alone. Incubate in 5% CO₂ at 37°C for one hour.
50 2. Prepare EGF ligand: dilute stock EGF in DMEM so that upon transfer of 10 µl dilute EGF (1:12 dilution), 25 nM final concentration is attained.
3. Prepare fresh 10 ml HNTG* sufficient for 100 µl per well wherein HNTG* comprises: HNTG stock (2.0 ml), milli-Q H₂O (7.3 ml), EDTA, 100 mM, pH 7.0 (0.5 ml), Na₃VO₄ 0.5 M (0.1 ml) and Na₄ (P₂O₇), 0.2 M (0.1 ml).
4. Place on ice.
55 5. After two hours incubation with drug, add prepared EGF ligand to cells, 10 µl per well, to yield a final concentration of 25 nM. Control wells receive DMEM alone. Incubate, shaking, at room temperature, for 5 minutes.
6. Remove drug, EGF, and DMEM. Wash cells twice with PBS. Transfer HNTG* to cells, 100 µl per well. Place on ice for 5 minutes. Meanwhile, remove blocking buffer from other ELISA plate and wash with TBST as described

EP 0 934 931 A2

above.

7. With a pipette tip securely fitted to a micropipettor, scrape cells from plate and homogenize cell material by repeatedly aspirating and dispensing the HNTG⁺ lysis buffer. Transfer lysate to a coated, blocked, and washed ELISA plate. Incubate shaking at room temperature for one hour.

8. Remove lysate and wash 4 times with TBST. Transfer freshly diluted anti-Ptyr antibody to ELISA plate at 100 μ l per well. Incubate shaking at room temperature for 30 minutes in the presence of the anti-Ptyr antiserum (1:3000 dilution in TBST).

9. Remove the anti-Ptyr antibody and wash 4 times with TBST. Transfer the freshly diluted TAGO 30 anti-rabbit IgG antibody to the ELISA plate at 100 μ l per well. Incubate shaking at room temperature for 30 minutes (anti-rabbit IgG antibody: 1:3000 dilution in TBST).

10. Remove detection antibody and wash 4 times with TBST. Transfer freshly prepared ABTS/H₂O₂ solution to ELISA plate, 100 μ l per well. Incubate at room temperature for 20 minutes. ABTS/H₂O₂ solution: 1.2 μ l 30% H₂O₂ in, 10 ml ABTS stock.

11. Stop reaction by adding 50 μ l 5N H₂SO₄ (optional), and determine O.D. at 410 nm.

12. The maximal phosphotyrosine signal is determined by subtracting the value of the negative controls from the positive controls. The percent inhibition of phosphotyrosine content for extract-containing wells is then calculated, after subtraction of the negative controls.

6.1.6. Cellular Insulin Receptor ELISA

[0274] The following protocol was used to determine whether the compounds of the present invention possessed insulin receptor tyrosine kinase activity.

[0275] **Materials And Reagents.** The following materials and reagents were used to measure phosphotyrosine levels on the insulin receptor (indicating insulin receptor tyrosine kinase activity):

1. The preferred cell line was an NIH3T3 cell line (ATCC No. 1658) which overexpresses Insulin Receptor (H25 cells);
2. H25 cells are grown in an incubator with 5% CO₂ at 37°C. The growth media is DMEM + 10% FBS (heat inactivated) + 2mm L-Glutamine;
3. For ELISA plate coating, the monoclonal anti-IR antibody named BBE is used. Said antibodies was purified by the Enzymology Lab, SUGEN, Inc.;
4. D-PBS, comprising:

KH ₂ P0 ₄	0.20 g/l (GIBCO, 310-4190AJ)
K ₂ HP0 ₄	2.16 g/l
KCl	0.20 g/l
NaCl	8.00 g/l (pH 7.2);

5. Blocking Buffer: TBST plus 5% Milk (Carnation Instant Non-Fat Dry Milk);

6. TBST buffer, comprising:

Tris-HCl	50mM
NaCl	150mM pH 7.2 (HCl, 1 N)
Triton X-100	0.1%

Note: Stock solution of TBS (10X) is prepared, and Triton X-100 is added to the buffer during dilution;

7. HNTG buffer, comprising:

EP 0 934 931 A2

HEPES	20mM
NaCl	150mM pH 7.2 (HCl, 1 N)
Glycerol	10%
Triton X-100	0.2%

Note: Stock solution (5X) is prepared and kept at 4°C;

8. EDTA.HCl: 0.5 M pH 7.0 (NaOH) as 100X stock;

9. Na₃VO₄: 0.5 M as 100X stock and aliquots are kept in -80°C;

10. Na₄P₂O₇: 0.2 M as 100X stock;

11. Insulin from GIBCO BRL (Cat# 18125039);

12. Polyclonal antiserum Anti-phosphotyrosine: rabbit sera generated by Enzymology Lab., SUGEN Inc.;

13. Detection antibody, preferably goat anti-rabbit IgG, POD conjugate, Tago (Cat. No. 4520: Lot No. 1802): Tago, Inc., Burlingame, CA;

14. ABTS solution, comprising:

Citric acid	100 mM
Na ₂ HPO ₄	250 mM pH 4.0 (1 N HCl)
ABTS	0.5 mg/ml

wherein ABTS is 2,2'-azinobis (3-ethylbenathiazoline sulfonic acid) and stored in the dark at 4°C and discarded when it turns green;

15. Hydrogen Peroxide: 30% solution is kept in the dark and at 40°C.

[0276] Protocol. All the following steps are conducted at room temperature unless it is specifically indicated. All ELISA plate washings are performed by rinsing the plate with tap water three times, followed by one TBST rinse. All plates were tapped dry with paper towels prior to use.

A. Cell Seeding:

[0277]

1. The cells were grown in tissue culture dish (10 cm, Corning 25020-100) to 80-90% confluence and harvested with Trypsin-EDTA (0.25%, 0.5 ml/D-100, GIBCO);

2. Resuspend the cells in fresh DMEM + 10% FBS + 2mM L-Glutamine, and transfer to 96 - well tissue culture plate (Corning, 25806-96) at 20,000 cells/well (100 µl/well). The cells are then incubated for 1 day. Following such incubation, 0.01% serum medium (90/µl) replaces the old media and the cells incubate in 5% CO₂ and 37°C overnight.

B. ELISA Plate Coating and Blocking:

[0278]

1. Coat the ELISA plate (Corning 25805-96) with Anti-IR Antibody at 0.5 µg/well in 100 µl PBS at least 2 hours.

2. Remove the coating solution, and replace with 100 µl blocking Buffer, and shake for 30 minutes. Remove the blocking buffer and wash the plate just before adding lysate.

EP 0 934 931 A2**C. Assay Procedures****[0279]**

1. The drugs are tested in serum-free condition.
2. Dilute drug stock (in 100% DMSO) 1:10 with DMEM in 96-well poly-propylene plate, and transfer 10 μ l/well of this solution to the cells to achieve final drug dilution 1:100, and final DMSO concentration of 1.0%. Incubate the cells in 5% CO₂ at 37°C for 2 hours.
3. Prepare fresh cells lysis buffer (HNTG*)

HNTG (5x)	2 ml
EDTA	0.1 ml
Na ₃ VO ₄	0.1 ml
Na ₄ P ₂ O ₇	0.1 ml
H ₂ O	7.3 ml
HNTG*	10 ml

4. After drug incubation for two hours, transfer 10 μ l/well of 1 μ M insulin in PBS to the cells (Final concentration = 100 nM), and incubate at 5% CO₂ at 37°C for 10 minutes.
5. Remove media and add 100 μ l/well HNTG* and shake for 10 minutes. Look at cells under microscope to see if they are adequately lysed.
6. Using a 12-channel pipette, scrape the cells from the plate, and homogenize the lysate by repeat aspiration and dispense. Transfer all the lysate to the antibody coated ELISA plate, and shake for 1 hour.
7. Remove the lysate, wash the plate, transfer anti-pTyr (1:3,000 with TBST) 100 μ l/well, and shake for 30 minutes.
8. Remove anti-pTyr, wash the plate, transfer Tago (1:3,000 with TBST) 100 μ l/well, and shake for 30 minutes.
9. Remove detection antibody, wash the plate, and transfer fresh ABTS/H₂O₂ (1.2 μ l H₂O₂ to 10 ml ABTS) 100 μ l/well to the plate to start color development.
10. Measure OD in Dynatec MR5000, which is connected to Ingres. All following steps should follow Ingres instruction.

6.1.7. Experimental Results From ELISA Assays

[0280] The experimental results for various compounds according to the invention using the above-described protocols are set forth at Table 1:

EP 0 934 931 A2

TABLE 1

ELISA Assay Results

COMPOUND (Example)	PDGFR IC50 (μ M)	FLK-1 IC50 (μ M)	EGFR IC50 (μ M)	HER2 Kinase IC50 (μ M)	IGF-1R IC50 (μ M)
27	19.4	0.8			
4313	14.5	18.8	11	16.9	8.0
18	12	0.39			
16	87.4	4.2			
17		11.8			
20		28.8			
21		9			
22		2.2			
24		8.5			
26		22.6			
28				22.5	
29	7.9	11.2			
32		20.9			
4	33.1	2.1			
33		21.6		39.4	
34		4.1			
5	5.8	1.6		90.2	
36		4		51.5	
37		9.6			
38		4.7			
39		14.8	36.7		
41		6.4			
8		2.9		89.8	
42		0.4			
43		1.8			
9	17	0.24			
44		23.8			
10		0.17			
45	53.7	1.1			
11		0.07			
12	10.8	0.11			
48		15.4			
13		2.3			
50		4.6			
14		2.4			
53		51.4			
15		4.5		70.6	
55		8.6			
57		73.4			
58		41.2			

EP 0 934 931 A2

COMPOUND (Example)	PDGFR IC50 (μ M)	FLK-1 IC50 (μ M)	EGFR IC50 (μ M)	HER2 Kinase IC50 (μ M)	IGF-1R IC50 (μ M)
59		22.8			
6		4.5		92.6	
61		3.4	44		
62	65.5	0.14			
64		36.2			
70		0.18			
71		20.3			
73	86	1.6			
74	55.9	2.7			
76		8.7			
77	14.2	1.5			
78		7.4			
81		0.15			
7		5.3	39.6	30.4	

6.2. Cell Growth Assays

[0281] The following assays may be conducted to measure the effect of the claimed compounds upon cell growth as a result of the compound's interaction with one or more RTKs. Unless otherwise specified, the following assays may be generally applied to measure the activity of a compound against any particular RTK. To the extent that an assay, set forth below, refers to a specific RTK, one skilled in the art would be able to adapt the disclosed protocol for use to measure the activity of a second RTK.

6.2.1. Soft Agar Assay

[0282] The soft agar assay may be used to measure the effects of substances on cell growth. Unless otherwise stated the soft agar assays were carried out as follows:

[0283] **Material And Reagents.** The following materials and reagents were used:

- a. A water bath set at 39°C and another water bath at 37°C.
- b. 2X assay medium is comprised of 2X Dulbecco's 5Modified Eagle's Medium (DMEM) (Gibco Cat. # CA400-4ANO3) supplemented by the following:
 - 20% Fetal Bovine Serum (FBS) 2 mM sodium pyruvate 4 mM glutamine amine; and
 - 20 mM HEPES Non-essential Amino Acids (1:50 from IOOx stock).
- c. 1X assay medium made of 1X DMEM supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM glutamine, 10 mM HEPES, non-essential amino acid (1:100 from IOOx stock).
- d. 1.6% SeaPlaque Agarose in autoclave bottle.
- e. Sterile 35 mm Corning plates (EMC Bioproducts Cat. #50102).
- f. Sterile 5 ml glass pipets (individually wrapped).
- g. Sterile 15 ml and 50 ml conical centrifuge tubes.
- h. Pipets and sterile tips.
- i. Sterile microcentrifuge tubes.
- j. Cells in T75 flasks: SKOV-3 (ATCC HTB77).
- k. 0.25% Trypsin solution (Gibco #25200-015).

[0284] **Procedure.** The following procedure was used to conduct the soft agar assay:

EP 0 934 931 A2**A. Procedure for making the base layer****[0285]**

- 5 1. Have all the media warmed up in the 37°C water bath.
2. To make 1X of assay medium + 0.8% agar: make a 1:2 (vol:vol) dilution of melted agar (cooled to 39°C), with 2X assay medium.
3. Keep all media with agar warm in the 39°C water bath when not in use.
4. Dispense 1 ml of 1X assay medium + 0.8% agar into dishes and gently swirl plate to form a uniform base layer.
- 10 Bubbles should be avoided.
5. Refrigerate base layers to solidify (about 20 minutes). Base layers can be stored overnight in the refrigerator.

B. Procedure for collecting cells**[0286]**

1. Take out one flask per cell line from the incubator; aspirate off medium; wash once with PBS and aspirate off; add 3 ml of trypsin solution.
2. After all cells dissociate from the flask, add 3 ml of 1X assay media to inhibit trypsin activity. Pipet the cells up and down, then transfer the suspension into a 15ml tube.
- 20 3. Determine the concentration of cells using a Coulter counter, and the viability by trypan blue exclusion.
4. Take out the appropriate volume needed to seed 3300 viable cells per plate and dilute it to 1.5 ml with 1X assay medium.

25 C. Procedure for making the upper 0.4% agarose layer:**[0287]**

1. Add TBST compounds at twice the desired final assay concentration; + 1.5 ml of cell suspension in 1X assay medium 10% FBS; + 1.5 ml of 1X assay medium + 0.8% agarose*: Total = 3.0 ml 1X media 10% FBS + 0.4% agarose with 3300 viable cells/ml, with and without TBST compounds.
2. Plate 1 ml of the Assay Mix onto the 1 ml base layer. The duplicates are plated from the 3 ml volume.
3. Incubate the dishes for 2-3 weeks in a 100% humidified, 10% CO₂ incubator.
- 35 4. Colonies that are 60 microns and larger are scored positive.

6.2.2. Sulforhodamine B (SRB) Growth Assays

[0288] The SRB assays may be used to measure the effects of substances or cell growth. The assays are carried out as follows:

40

Assay 1: 3T3/E/H+TGF- α (T) Cell Growth SRB Assay**Materials:****45 [0289]**

- 96-well flat bottom sterile plates
- 96-well round bottom sterile plates
- sterile 25 ml or 100 ml reservoir
- 50 pipets, multi-channel pipetman
- sterile pipet tips
- sterile 15 ml and 50 ml tubes

Reagents:

55

[0290]

* (Made by 1:2 dilution of 2X media with 1.6% agar 30 for the base layer procedure above.)

EP 0 934 931 A2

0.4% SRB in 1% acetic acid
10 mM Tris base
10% TCA
1% acetic acid
sterile DMSO (Sigma)
compound in DMSO (100 mM or less stock solution)
25% Trypsin-EDTA in Cell Dissociation Solution (Sigma)

Cell line and growth medium:

[0291]

3T3/E/H+TGF- α (T) (NIH 3T3 clone 7 cells expressing EGF-R/HER2 chimera and TGF- α , tumor-derived autocrine loop cells)
2% calf serum/DMEM + 2 mM glutamine

Protocol:

[0292]

Day 0: Cell Plating:

This part of assay is carried out in a laminar flow hood.

1. Trypsinize cells as usual. Transfer 100 μ l of cell suspension to 10 ml of isotone. Count cells with the Coulter Counter.
2. Dilute cells in growth medium to 60,000, cells/ml. Transfer 100 μ l of cells to each well in a 96-well flat bottom plate to give 6000 cells/well.
3. Use half of plate (4 rows) for each compound and quadruplicate wells for each compound concentration, a set of 4 wells for medium control and 4 wells for DMSO control.
4. Gently shake plates to allow for uniform attachment of the cells.
5. Incubate the plates at 37°C in a 10% CO₂ incubator.

Day 1: Addition of Compound:

This part of assay is carried out in a laminar flow hood.

1. In 96 well-round bottom plate, add 125 μ l of growth medium to columns 3 to 11. This plate is used to titrate out the compound, 4 rows per compound.
2. In a sterile 15 ml tube, make a 2X solution of the highest concentration of compound by adding 8 μ l of the compound to a total of 2 ml growth medium for a dilution of 1:250. At this dilution, the concentration of DMSO is 0.4% for a 2X solution or 0.2% for 1X solution on the cells. The starting concentration of the compound is usually 100 μ M but this concentration may vary depending upon the solubility of the compound.
3. Transfer the 2X starting compound solution to quadruplicate wells in column 12 of the 96-well round bottom plate. Do 1:2 serial dilutions across the plate from right to left by transferring 125 μ l from column 12 to column 11, column 11 to 10 and so on. Transfer 100 μ l of compound dilutions onto 100 μ l medium on cells in corresponding wells of 96-well flat bottom plate. Total volume per well should be 200 μ l.
4. For vehicle control, prepare a 2X solution of DMSO at 0.4% DMSO in growth medium. Transfer 100 μ l of the DMSO solution to the appropriate wells of cells. The final concentration of DMSO is 0.2%.
5. For the medium control wells, add 100 μ l/well of growth medium to the appropriate wells of cells.
6. Return the plate to the incubator and incubate for 4 days.

Day 5: Development of Assay

This part of assay is carried out on the bench.

1. Aspirate or pour off medium. Add 200 μ l cold 10% TCA to each well to fix cells. Incubate plate for at least 60 min. at 4°C.
2. Discard TCA and rinse wells 5 times with water. Dry plates upside down on paper towels.
3. Stain cells with 100 μ l/well 0.4% SRB for 10 min.
4. Pour off SRB and rinse wells 5 times with 1% acetic acid. Dry plates completely upside down on paper tow-

EP 0 934 931 A2

els.

5. Solubilize dye with 100 µl/well 10 mM Tris base for 5-10 min. on shaker.

6. Read plates on Dynatech ELISA Plate Reader at 570 nm with reference at 630 nm.

5 **Assay 2: 3T3/EGF-R+TGF-α(T) Cell Growth SRB Assay**

Materials and Reagents same as for Assay 1.

Cell line and growth medium:

10 [0293]

3T3/EGF-R+TGF-α(T) (NIH 3T3 clone 7 cells expressing EGF-R and TGF-α, tumor-derived autocrine loop cells)
2% calf serum/DMEM + 2 mM glutamine

15 Protocol:

[0294]

20 Day 0: Cell Plating:

This part of assay is carried out in a laminar flow hood.

1. Trypsinize cells as usual. Transfer 100 µl of cell suspension to 10 ml of isotone. Count cells with the Coulter Counter.
- 25 2. Dilute cells in growth medium to 60,000 cells/ml. Transfer 100 µl of cells to each well in a 96-well flat bottom plate to give 6000 cells/well.
3. Use half of plate (4 rows) for each compound and quadruplicate wells for each compound concentration, a set of 4 wells for medium control and 4 wells for DMSO control.
4. Gently shake plates to allow for uniform attachment of the cells.
- 30 5. Incubate the plates at 37°C in a 10% CO₂ incubator.

Day 1: Addition of Compound: same as for Assay 1.

Day 5: Development of Assay: same as for Assay 1.

35 **Assay 3: 3T3/PDGF-βR/PDGF-BB(T) Cell Growth SRB Assay**

Cell line and growth medium:

[0295]

- 40 3T3/PDGF-βR/PDGF-BB(T) (NIH 3T3 clone 7 cells expressing PDGF β-receptor and PDGF-BB, from tumors resected from athymic mice)
2% calf serum/DMEM + 2 mM glutamine

45 Protocol:

[0296]

Day 0: Cell Plating:

50 This part of assay is carried out in a laminar flow hood.

1. Trypsinize cells as usual. Transfer 200 µl of cell suspension to 10 ml of isotone. Count cells on the Coulter Counter.
2. Dilute cells in growth medium to 60,000 cells/ml. Transfer 100 µl of cells to each well in a 96-well flat bottom plate to give 6000 cells/well.
- 55 3. Allow half of plate (4 rows) for each compound and quadruplicate wells for each compound concentration, a set of 4 wells for medium control and 4 wells for DMSO control.
4. Gently shake plates to allow for uniform attachment of the cells to the plate.

EP 0 934 931 A2

5. Incubate the plates at 37°C in a 10% CO₂ incubator.

Day 1: Addition of Compound: same as for Assay 1.

Day 5: Development of Assay: same as for Assay 1.

Assay 4: Human Smooth Muscle Cells (SMC) Growth SRB Assay

Materials and Reagents same as for Assay 1:

Cell line and growth medium:

[0297]

Human Aortic Smooth Muscle cells (Clonetics)

Clonetics's Bullet Kit: Smooth Muscle Basal Medium (SmBM) which is modified MCDB 131 containing fetal bovine serum (5%), hFGF (2ng/ml), hEGF (0.1 ng/ml), insulin (5.0 ug/ml), gentamicin (50ug/ml) and amphotericin B (50 ng/ml)

Protocol:**[0298]**

Day 0: Cell plating:

This part of assay is carried out in a laminar flow hood.

1. Trypsinize cells as usual. Transfer 200 µl of cell suspension to 10 ml of isotone. Count cells on the Coulter Counter.

2. Dilute cells in growth medium to 20,000 cells/ml. Transfer 100 µl of cells to each well in a 96-well flat bottom plate to give 2000 cells/well.

3. Allow half of plate (4 rows) for each compound and quadruplicate wells for each compound concentration, a set of 4 wells for medium control and 4 wells for DMSO control.

4. Gently shake plates to allow for uniform attachment of the cells to the plate.

5. Incubate the plates at 37°C in a 10% CO₂ incubator.

Day 1: Addition of Compound: same as for Assay 1.

Day 5: Development of Assay: same as for Assay 1.

6.2.3. 3T3 Cell Growth Assay**Assay 1: PDGF-Induced BrdU Incorporation Assay****Materials and Reagents:****[0299]**

(1) PDGF: human PDGF B/B; 1276-956, Boehringer Mannheim, Germany

(2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(5) TMB Substrate Solution: tetramethylbenzidine (TMB), ready to use, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(6) PBS Washing Solution : 1X PBS, pH 7.4, made in house.

(7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.

EP 0 934 931 A2

Protocol**[0300]**

- 5 (1) 3T3 engineered cell line: 3T3/EGFRc7.
- (2) Cells are seeded at 8000 cells/well in DMEM, 10% CS, 2mM Gln in a 96 well plate. Cells are incubated overnight at 37°C in 5% CO₂.
- (3) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0%CS DMEM with 0.1% BSA) for 24 hours.
- 10 (4) On day 3, ligand (PDGF=3.8 nM, prepared in DMEM with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (PDGF) but no test compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.
- (5) After 20 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration=10 µM) for 1.5 hours.
- 15 (6) After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 µl/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.
- (7) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 µl/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.
- 20 (8) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 µl/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.
- 25 (9) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.
- (10) TMB substrate solution is added (100 µl/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.
- 30 (11) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

Assay 2: EGF-Induced BrdU Incorporation AssayMaterials and Reagents

35

[0301]

- (1) EGF: mouse EGF, 201; Toyobo, Co., Ltd Japan
- (2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- 40 (3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- (4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- (5) TMB Substrate Solution: tetramethylbenzidine (TMB), ready to use, Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- 45 (6) PBS Washing Solution : 1X PBS, pH 7.4, made in house.
- (7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.

Protocol

50

[0302]

- (1) 3T3 engineered cell line: 3T3/EGFRc7
- (2) Cells are seeded at 8000 cells/well in 10% CS, 2mM Gln in DMEM, in a 96 well plate. Cells are incubated overnight at 37°C in 5% CO₂.
- 55 (3) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0%CS DMEM with 0.1% BSA) for 24 hours.
- (4) On day 3, ligand (EGF=2 nM, prepared in DMEM with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells

EP 0 934 931 A2

receive the ligand (EGF) but no test compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.

5) After 29 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration=10 μ M) for 1.5 hours.

6) After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 μ l/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.

7) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.

8) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 μ l/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.

9) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.

10) TMB substrate solution is added (100 μ l/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.

11) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

Assay 3: EGF-Induced Her2 -Driven BrdU Incorporation**Materials and Reagents:****[0303]**

(1) EGF: mouse EGF, 201; Toyobo, Co., Ltd. Japan

(2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(5) TMB Substrate Solution: tetramethylbenzidine (TMB), ready to use, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(6) PBS Washing Solution: 1X PBS, pH 7.4, made in house.

(7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.

Protocol:**[0304]**

(1) 3T3 engineered cell line: 3T3/EGFr/Her2/EGFr (EGFr with a Her2 kinase domain)

(2) Cells are seeded at 8000 cells/well in DMEM, 10% CS, 2mM Gln in a 96- well plate. Cells are incubated overnight at 37° in 5% CO₂.

(3) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0%CS DMEM with 0.1% BSA) for 24 hours.

(4) On day 3, ligand (EGF=2 nM, prepared in DMEM with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (EGF) but no test compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.

5) After 20 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration=10 μ M) for 1.5 hours.

6) After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 μ l/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.

7) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.

8) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solu-

EP 0 934 931 A2

tion (1:100 dilution in PBS, 1% BSA) is added (100 µl/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.

(9) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.

(10) TMB substrate solution is added (100 µl/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.

(11) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

Assay 4: IGF1-Induced BrdU Incorporation Assay**Materials and Reagents:****[0305]**

(1) IGF1 Ligand: human, recombinant; G511, Promega Corp, USA.

(2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(5) TMB Substrate Solution: tetramethylbenzidine (TMB), ready to use, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(6) PBS Washing Solution : 1X PBS, pH 7.4, made in house.

(7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.

Protocol:**[0306]**

(1) 3T3 engineered cell line: 3T3/IGF1r.

(2) Cells are seeded at 8000 cells/well in DMEM, 10% CS, 2mM Gln in a 96- well plate. Cells are incubated overnight at 37°C in 5% CO₂.

(3) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0%CS DMEM with 0.1% BSA) for 24 hours.

(4) On day 3, ligand (IGF1=3.3 nM, prepared in DMEM with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (IGF1) but no test compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.

(5) After 16 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration=10 µM) for 1.5 hours.

(6) After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 µl/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.

(7) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 µl/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.

(8) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 µl/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.

(9) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.

(10) TMB substrate solution is added (100 µl/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.

(11) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

EP 0 934 931 A2

Assay 5: Insulin-Induced BrdU Incorporation Assay

Materials and Reagents:

5 [0307]

- (1) Insulin: crystalline, bovine, Zinc; 13007, Gibco BRL, USA.
- (2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- (3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- 10 (4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- (5) TMB Substrate Solution: tetramethylbenzidine (TMB), ready to use, Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- (6) PBS Washing Solution : 1X PBS, pH 7.4, made in house.
- 15 (7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.

Protocol:

[0308]

20

- (1) 3T3 engineered cell line: H25
- (2) Cells are seeded at 8000 cells/well in DMEM, 10% CS, 2mM Gln in a 96 well plate. Cells are incubated overnight at 37°C in 5% CO₂.
- (3) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0%CS DMEM with 0.1% BSA) for 24 hours.
- 25 (4) On day 3, ligand (Insulin=10 nM, prepared in DMEM with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (Insulin) but no test compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.
- 30 (5) After 16 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration=10 µM) for 1.5 hours.
- (6) After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 µl/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.
- 35 (7) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 µl/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.
- (8) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 µl/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.
- 40 (9) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.
- (10) TMB substrate solution is added (100 µl/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.
- 45 (11) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

6.2.4. HUV-EC-C Assay

50 [0309] The following protocol may also be used to measure a compound's activity:

DAY 0

[0310]

55

1. Wash and trypsinize HUV-EC-C cells (human umbilical vein endothelial cells, (American Type Culture Collection; catalogue no. 1730 CRL). Wash with Dulbecco's phosphate-buffered saline (D-PBS; obtained from Gibco BRL; catalogue no. 14190-029) 2 times at about 1 ml/10 cm² of tissue culture flask. Trypsinize with 0.05% trypsin-EDTA in

EP 0 934 931 A2

non-enzymatic cell dissociation solution (Sigma Chemical Company; catalogue no. C-1544). The 0.05% trypsin was made by diluting 0.25% trypsin/1 mM EDTA (Gibco, catalogue no. 25200-049) in the cell dissociation solution. Trypsinize with about 1 ml/25-30 cm² of tissue culture flask for about 5 minutes at 37°C. After cells have detached from the flask, add an equal volume of assay medium and transfer to a 50 ml sterile centrifuge tube (Fisher Scientific; catalogue no. 05-539-6).

2. Wash the cells with about 35 ml assay medium in the 50 ml sterile centrifuge tube by adding the assay medium, centrifuge for 10 minutes at approximately 200xg, aspirate the supernatant, and resuspend with 35 ml D-PBS. Repeat the wash two more times with D-PBS, resuspend the cells in about 1 ml assay medium/15 cm² of tissue culture flask. Assay medium consists of F12K medium (Gibco BRL; catalogue no. 21127-014) + 0.5% heat-inactivated fetal bovine serum. Count the cells with a Coulter Counter[®] (Coulter Electronics, Inc.) and add assay medium to the cells to obtain a concentration of 0.8-1.0x10⁵ cells/ml.

3. Add cells to 96-well flat-bottom plates at 100 µl/well or 0.8-1.0x10⁴ cells/well; incubate ~24h at 37°C, 5% CO₂.

DAY 1

[0311]

1. Make up two-fold drug titrations in separate 96-well plates, generally 50 µM on down to 0 µM. Use the same assay-medium as mentioned in day 0, step 2 above. Titrations are made by adding 90 µl/well of drug at 200 µM (4X the final well concentration) to the top well of a particular plate column. Since the stock drug concentration is usually 20 mM in DMSO, the 200 µM drug concentration contains 2% DMSO.

Therefore, diluent made up to 2% DMSO in assay medium (F12K + 0.5% fetal bovine serum) is used as diluent for the drug titrations in order to dilute the drug but keep the DMSO concentration constant. Add this diluent to the remaining wells in the column at 60 µl/well. Take 60 µl from the 120 µl of 200 µM drug dilution in the top well of the column and mix with the 60 µl in the second well of the column. Take 60 µl from this well and mix with the 60 µl in the third well of the column, and so on until two-fold titrations are completed. When the next-to-the-last well is mixed, take 60 µl of the 120 µl in this well and discard it. Leave the last well with 60 µl of DMSO/media diluent as a non-drug-containing control. Make 9 columns of titrated drug, enough for triplicate wells each for 1) VEGF (obtained from Pepro Tech Inc., catalogue no. 100-200, 2) endothelial cell growth factor (ECGF) (also known as acidic fibroblast growth factor, or aFGF) (obtained from Boehringer Mannheim Biochemica, catalogue no. 1439 600), and assay media control. ECGF comes as a preparation with sodium heparin.

2. Transfer 50 µl/well of the drug dilutions to the 96-well assay plates containing the 0.8-1.0x10⁴ cells/100 µl/well of the HUV-EC-C cells from day 0 and incubate ~2 h at 37°C, 5% CO₂.

3. In triplicate, add 50 µl/well of 80 µg/ml VEGF, 20 ng/ml ECGF, or media control to each drug condition. As with the drugs, the growth factor concentrations are 4X the desired final concentration. Use the assay media from day 0 step 2 to make the concentrations of growth factors. Incubate approximately 24 hours at 37°C, 5% CO₂. Each well will have 50 µl drug dilution, 50 µl growth factor or media, and 100 µl cells, = 200 µl/well total. Thus the 4X concentrations of drugs and growth factors become 1X once everything has been added to the wells.

DAY 2

[0312]

1. Add ³H-thymidine (Amersham; catalogue no. TRK-686) at 1 µCi/well (10 µl/well of 100 µCi/ml solution made up in RPMI media + 10% heat-inactivated fetal bovine serum) and incubate ~24 h at 37°C, 5% CO₂. Note: ³H-thymidine is made up in RPMI media because all of the other applications for which we use the ³H-thymidine involve experiments done in RPMI. The media difference at this step is probably not significant. RPMI was obtained from Gibco BRL, catalogue no. 11875-051.

DAY 3

[0313]

1. Freeze plates overnight at -20°C.

EP 0 934 931 A2**DAY 4****[0314]**

- 5 1. Thaw plates and harvest with a 96-well plate harvester (Tomtec Harvester 96^(R)) onto filter mats (Wallac; catalogue no. 1205-401); read counts on a Wallac Betaplate^(TM) liquid scintillation counter.

6.2.5. PDGF-R Cellular Assay

- 10 **[0315]** The PDGF cellular kinase assay was carried out as follows: cells are lysed in 0.2 M Hepes, 0.15 M NaCl, 10% V/V glycerol, 0.04% Triton X-100, 5 mM EDTA, 5 mM sodium vanadate and 2 mM Na⁺ pyrophosphate; cell lysates are then added to an ELISA plate coated with an anti-PDGF receptor antibody (Genzyme); ELISA plates are coated at 0.5 µg of antibody/well in 150 µl of PBS for 18 hours at 4°C prior to the addition of the lysate; the lysate is incubated in the coated plates for 1 hour and then washed four times in TBST (35 mM Tris-HCl pH 7.0, 0.15 M NaCl, 0.1% Triton X100);
15 anti-phosphotyrosine antibody (100 µl in PBS) is added and the mixture is incubated for 30 minutes at room temperature; the wells were then washed four times in TBST, a secondary antibody conjugated to POD (TAGO) is added to each well, and the treated well are incubated for 30 minutes at room temperature; the wells are then washed four times in TBST, ABTS/H₂O₂ solution is added to each well and the wells are incubated for two minutes; absorbance is then measured at 410 nm.

20

6.2.6. Experimental Results Of Cell Growth Assay

- [0316]** Results for various compounds obtained from the above-described assays are set forth in the Tables that follow:

25

30

35

40

45

50

55

EP 0 934 931 A2

TABLE 2

Mitogenesis in Endothelial Cells
[3H]Thymidine Incorporation

COMPOUND (Example)	HUV-EC VEGF (μ M)	Assay a-FGF (μ M)
27	1.1	153.8
1B	0.2	6.0
16	6.6	3.4
17	4.8	35.7
4796	30.7	35.8
20	43.2	
21	19.9	
22	2.5	45.2
23	1.6	4.6
24	14.8	
25	3.4	3.7
26	25.6	19.3
28	8.0	13.0
29	34.3	16.3
30	1.0	1.4
32	4.4	4.9
4	0.6	
33	46.1	27.3
5	0.8	25.8
5201	2.5	2.3
36	2.3	0.7
37	5.1	11.8
38	2.9	130
5217	9.6	10.5

EP 0 934 931 A2

COMPOUND (Example)	HUV-EC	Assay
	VEGF (μM)	a-FGF (μM)
41	2.4	2.7
8	2.2	
42	<0.8	2.0
9	<0.8	31.1
44	0.9	0.6
10	<0.8	
45	39.8	35.5
11	<0.8	22.7
5409	26.0	
12	<0.8	
48	13.6	40
13	0.7	
50	11.4	
14	2.5	
15	5.7	
5429	27.6	
59	0.16	0.14
60	39.8	33.0
61	1.2	30.0
63	3.8	3.4
64	20	20
68	<0.07	<0.07
69	0.5	0.8
70	0.14	7.9
71	3.8	12.9
73	1.3	3.2
74	0.54	8.7
76	2.0	5.0
77	1.2	14.1
81	0.05	37.8

EP 0 934 931 A2

COMPOUND (Example)	HUV-EC Assay	
	VEGF (μM)	α -FGF (μM)
7	1.2	3.8

TABLE 3

Mitogenesis in 3T3/EGFR Cells BrdU Incorporation			
COMPOUND (Example)	PDGFR PDGF Ligand IC50 (μM)	FGFR FGF Ligand IC50 (μM)	EGFR EGF Ligand IC50 (μM)
27	75		
4313	6	5.5	5.5
1B	2.5		
29	9	4.9	60
4	3	10	20
5402	50	40	
36	3	25	
10	5.2		
45	7.5	70	100
12	2.8	70	
61	30	16	
5463			23
71	70	60	95
5465	40	25	50
73	18	15	17
74	8		
5469	4	15	28
77	4	50	54
81	6.5	9	48

TABLE 4

Cell Growth Assay on Various Cell Lines SRB Readout				
COMPOUND (Example)	3T3/E/H+ TGF- α (T) IC50 (μM)	3T3/EGFR+ TGF- α (T) IC50 (μM)	3T3/PDGFR+ PDGF(T) IC50 (μM)	SMC IC50 (μM)
27	36			
4313	32	10.7		8.8
1B	78		10	

EP 0 934 931 A2

TABLE 4 (continued)

Cell Growth Assay on Various Cell Lines SRB Readout				
COMPOUND (Example)	3T3/E/H+ TGF- α (T) IC ₅₀ (μ M)	3T3/EGFR+ TGF- α (T) IC ₅₀ (μ M)	3T3/PDGFR+ PDGF(T) IC ₅₀ (μ M)	SMC IC ₅₀ (μ M)
5			22.2	
3T3/E/H+TGF- α (T): NIH 3T3 cells expressing EGFR/HER2 chimera and TGF- α , tumor-derived 3T3/EGFR+TGF- α (T): NIH 3T3 cells expressing EGFR and TGF- α , tumor-derived 3T3/PDGFR+PDGF(T): NIH 3T3 cells expressing PDGF- β R and PDGF- β β , tumor-derived SMC: human smooth muscle cells from Clonetics				

6.3. Measurement of Cell Toxicity

[0317] Therapeutic compounds should be more potent in inhibiting receptor tyrosine kinase activity than in exerting a cytotoxic effect. A measure of the effectiveness and cell toxicity of a compound can be obtained by determining the therapeutic index: IC₅₀/LD₅₀. IC₅₀, the dose required to achieve 50% inhibition, can be measured using standard techniques such as those described herein. LD₅₀, the dosage which results in 50% toxicity, can also be measured by standard techniques (Mossman, 1983, *J. Immunol. Methods*, 65:55-63), by measuring the amount of LDH released (Korzeniewski and Callewaert, 1983, *J. Immunol. Methods* 64:313; Decker and Lohmann-Matthes, 1988, *J. Immunol. Methods* 115:61), or by measuring the lethal dose in animal models. Compounds with a large therapeutic index are preferred. The therapeutic index should be greater than 2, preferably at least 10, more preferably at least 50.

6.3. In Vivo Animal Models

6.3.1. Xenograft Animal Models

[0318] The ability of human tumors to grow as xenografts in athymic mice (e.g., Balb/c, nu/nu) provides a useful in vivo model for studying the biological response to therapies for human tumors. Since the first successful xenotransplantation of human tumors into athymic mice, (Rygaard and Povlsen, 1969, *Acta Pathol. Microbiol. Scand.* 77:758-760), many different human tumor cell lines (e.g., mammary, lung, genitourinary, gastrointestinal, head and neck, glioblastoma, bone, and malignant melanomas) have been transplanted and successfully grown in nude mice. Human mammary tumor cell lines, including MCF-7, ZR75-1, and MDA-MB-231, have been established as subcutaneous xenografts in nude mice (Warri *et al.*, 1991, *Int. J. Cancer* 49:616-623; Ozzello and Sordat, 1980, *Eur. J. Cancer* 16:553-559; Osborne *et al.*, 1985, *Cancer Res.* 45:584-590; Seibert *et al.*, 1983, *Cancer Res.* 43:2223-2239).

Assay 1: HER2/Xenograft Animal Model

[0319] To study the effect of anti-tumor drug candidates on HER2 expressing tumors, the tumor cells should be able to grow in the absence of supplemental estrogen. Many mammary cell lines are dependent on estrogen for in vivo growth in nude mice (Osborne *et al.*, *supra*), however, exogenous estrogen suppresses HER2 expression in nude mice (Warri *et al.*, *supra*; Dati *et al.*, 1990, *Oncogene* 5:1001-1006). For example, in the presence of estrogen, MCF-7, ZR-75-1, and T47D cells grow well *in vivo*, but express very low levels of HER2 (Warri *et al.*, *supra*; Dati *et al.*, *supra*).

[0320] The following type of xenograft protocol can be used:

- 1) implant tumor cells (subcutaneously) into the hindflank of five- to six-week-old female Balb/c nu/nu athymic mice;
- 2) administer the anti-tumor compound;
- 3) measure tumor growth by measuring tumor volume.

[0321] The tumors can also be analyzed for the presence of a receptor, such as HER2, EGF or PDGF, by Western and immunohistochemical analyses. Using techniques known in the art, one skilled in the art can vary the above procedures, for example through the use of different treatment regimes.

Assay 2: FLK-1/Xenograft Model.

[0322] The ability of the compounds of the present invention to inhibit ovarian, melanoma, prostate, lung and mammary tumor cell lines established as SC xenografts was examined. These studies were conducted using doses ranging from 1 to 75 mg/kg/day.

EP 0 934 931 A2

[0323] Materials And Methods. The tumor cells were implanted subcutaneously into the indicated strains of mice. Treatment was initiated on day 1 post implantation unless otherwise indicated (e.g. treatment of the SCID mouse related to the A375 melanoma cell line began on Day 9). Eight (8) to sixteen (16) mice comprised each test group.

5 Specifically:

[0324] Animals. Female athymic mice (BALB/c, nu/nu), BALB/c mice, Wistar rats and Fisher 344 rats were obtained from Simonsen Laboratories (Gilroy, CA). Female A/I mice were obtained from Jackson Laboratory (Bar Harbor, ME). DA rats were obtained from B&K Universal, Inc. (Fremont, CA). Athymic R/Nu rats, DBA/2N mice, and BALB/c mice were obtained from Harlan Sprague Dawley (Indianapolis, IN). Female C57BL/6 mice were obtained from Taconic (Germantown, NY). All animals were maintained under clean-room conditions in Micro-isolator cages with Alpha-dri bedding. They received sterile rodent chow and water *ad libitum*.

[0325] All procedures were conducted in accordance with the *NIH Guide for the Care and Use Of Laboratory Animals*.

[0326] Subcutaneous Xenograft Model. Cell lines were grown in appropriate medium as described (See Section 6). Cells were harvested at or near confluency with 0.05% Trypsin-EDTA and pelleted at 450 x g for 10 min. Pellets were resuspended in sterile PBS or media (without FBS) to a suitable concentration indicated in the Figure legends and the cells were implanted into the hindflank of mice. Tumor growth was measured over 3 to 6 weeks using vernier calipers tumor volumes were calculated as a product of length x width x height unless otherwise indicated. P values were calculated using the Students' t-test. Compound in 50 - 100 μ L excipient (dimethylsulfoxide, PBTE, PBTE6C:D5W, or PBTE:D5W) was delivered by IP injection at concentrations indicated in the Figure legends.

[0327] Intracerebral Xenograft Model. For the mouse IC model, rat C6 glioma cells were harvested and suspended in sterile PBS at a concentration of 2.5×10^7 cells/ml and placed on ice. Cells were implanted into BALB/c, nu/nu mice in the following manner: the frontoparietal scalps of mice were shaved with animal clippers if necessary before swabbing with 70% ethanol. Animals were anesthetized with isofluorane and the needle was inserted through the skull into the left hemisphere of the brain. Cells were dispensed from Hamilton Gas-tight Syringes using 30 ga 1/2 inch needles fitted with sleeves that allowed only a 3 mm penetration. A repeater dispenser was used for accurate delivery of 4 μ L of cell suspension. Animals were monitored daily for well-being and were sacrificed when they had a weight loss of about 40% and/or showed neurological symptoms.

[0328] For the rat IC model, rats (Wistar, Sprague Dawley, Fisher 344, or athymic R/Nu; approximately 200-400 g (some 3-400g)) were anesthetized by an IP injection of 100 mg/kg Ketaset (ketamine hydrochloride; Aveco, Fort Dodge, Iowa) and 5 mg/kg Rompun (xylazine, 2% solution; Bayer, Germany). After onset of anesthesia, the scalp was shaved and the animal was oriented in a stereotaxic apparatus (Stoelting, Wood Dale, IL). The skin at the incision site was cleaned 3 times with alternating swabs of 70% ethanol and 10% Povidone-Iodine. A median 1.0 - 1.5 cm incision was made in the scalp using a sterile surgical blade. The skin was detached slightly and pulled to the sides to expose the sutures on the skull surface. A dental drill (Stoelting, Wood Dale, IL) was used to make a small (1-2 mm diameter) burrhole in the skull approximately 1 mm anterior and 2 mm lateral to the bregma. The cell suspension was drawn into a 50 μ L Hamilton syringe fitted with a 23 or 25g standard bevel needle. The syringe was oriented in the burrhole at the level of the arachnoidea and lowered until the tip of the needle was 3 mm deep into the brain structure, where the cell suspension was slowly injected. After cells were injected, the needle was left in the burrhole for 1-2 minutes to allow for complete delivery of the cells. The skull was cleaned and the skin was closed with 2 to 3 sutures. Animals were observed for recovery from surgery and anesthesia. Throughout the experiment, animals were observed at least twice each day for development of symptoms associated with progression of intracerebral tumor. Animals displaying advanced symptoms (leaning, loss of balance, dehydration, loss of appetite, loss of coordination, cessation of grooming activities, and/or significant weight loss) were humanely sacrificed and the organs and tissues of interest were resected.

[0329] Intraperitoneal Model. Cell lines were grown in the appropriate media. Cells were harvested and washed in sterile PBS or medium without FBS, resuspended to a suitable concentration, and injected into the IP cavity of mice of the appropriate strain. Mice were observed daily for the occurrence of ascites formation. Individual animals were sacrificed when they presented with a weight gain of 40%, or when the IP tumor burden began to cause undue stress and pain to the animal.

6.3.2. In Vivo VEGF Pellet Model

[0330] In the following example, the Pellet Model was used to test a compound's activity against the FLK-1 receptor and against disorders associated with the formation of blood vessels. In this model, VEGF is packaged into a time-release pellet and implanted subcutaneously on the abdomen of nude mice to induce a 'reddening' response and subsequent swelling around the pellet. Potential FLK-1 inhibitors may then be implanted in methylcellulose near the VEGF pellet to determine whether such inhibitor may be used to inhibit the "reddening" response and subsequent swelling.

[0331] Materials And Methods. The following materials were used:

EP 0 934 931 A2

1) VEGF- human recombinant lyophilized product is commercially may be obtained from Peprotech, Inc., Princeton Business Park, G2; P.O. box 275, Rocky Hill, NJ 08553.

2) VEGF packaged into 21 day release pellets were obtained from Innovative Research of America (Innovative Research of America, 3361 Executive Parkway, P.O. Box 2746, Toledo, Ohio 43606), using patented matrix driven delivery system. Pellets were packaged at 0.20, 0.21, or 2.1 µg VEGF/pellet. These doses approximate 10 and 100 ng/day release of VEGF.

3) Methylcellulose

4) Water (sterile)

5) Methanol

6) Appropriate drugs/inhibitors

7) 10 cm culture plates

8) parafilm

[0332] The following protocol was then followed to conduct the VEGF pellet model:

1) VEGF, purchased from Peprotech, was sent to Innovative Research for Custom Pellet preparation;

2) Methylcellulose prepared at 1.5% (w/v) in sterile water;

3) Drugs solubilized in methanol (usual concentration range = 10 to 20 mg/ml);

4) Place sterile parafilm in sterile 10 cm plates;

5) 150 µl of drug in methanol added to 1.35 ml of 1.5% methylcellulose and mixed/vortexed thoroughly;

6) 25 µl aliquots of homogenate placed on parafilm and dried into discs;

7) Mice (6-10 wk. Balb/C athymic nu/nu, female) were anesthetized via isoflurane inhalation; 8) VEGF pellets and methylcellulose discs were implanted subcutaneously on the abdomen; and

9) Mice were scored at 24 hours and 48 hours for reddening and swelling response.

[0333] The specific experimental design used in this example was:

N = 4 animals/group

Controls: VEGF pellet + drug placebo

VEGF placebo + drug pellet

[0334] **Experimental Results.** The compounds of the present invention are expected to demonstrate activity according to this assay.

6.3.3. Mammary Fat Pad Model

[0335] Because of the established role played by many of the RTKs, *e.g.*, the HER2 receptor, in breast cancer, the mammary fat pad model is particularly useful for measuring the efficacy of compounds which inhibit such RTKs. By implanting tumor cells directly into the location of interest, *in situ* models more accurately reflect the biology of tumor development than do subcutaneous models. Human mammary cell lines, including MCF-7, have been grown in the mammary fat pad of athymic mice. Shafie and Grantham, 1981, *Natl. Cancer Instit.* 67:51-56; Gottardis *et al.*, 1988, *J. Steroid Biochem.* 30:311-314. More specifically, the following procedure can be used to measure the inhibitory effect of a compound on the HER2 receptor:

1) Implant, at various concentrations, MDA-MB-231 and MCF-7 cells transfected with HER-2 into the axillary mammary fat pads of female athymic mice;

2) Administer the compound; and

3) Measure the tumor growth at various time points.

[0336] The tumors can also be analyzed for the presence of a receptor such as HER2, by Western and immunohistochemical analyses. Using techniques known in the art, one skilled in the art can vary the above procedures, for example through the use of different treatment regimes.

6.3.4. Tumor Invasion Model

[0337] The following tumor invasion model has been developed and may be used for the evaluation of therapeutic value and efficacy of the compounds identified to selectively inhibit KDR/FLK-1 receptor.

EP 0 934 931 A2

6.3.4.1. Procedure

[0338] 8 week old nude mice (female) (Simonsen Inc.) were used as experimental animals. Implantation of tumor cells was performed in a laminar flow hood. For anesthesia, Xylazine/Ketamine Cocktail (100 mg/kg ketamine and 5 mg/kg) are administered intraperitoneally. A midline incision is done to expose the abdominal cavity (approximately 1.5 cm in length) to inject 10^7 tumor cells in a volume of 100 μ l medium. The cells are injected either into the duodenal lobe of the pancreas or under the serosa of the colon. The peritoneum and muscles are closed with a 6-0 silk continuous suture and the skin was closed by using wound clips. Animals were observed daily.

6.3.4.2. Analysis

[0339] After 2-6 weeks, depending on gross observations of the animals, the mice are sacrificed, and the local tumor metastases, to various organs (lung, liver, brain, stomach, spleen, heart, muscle) are excised and analyzed (measurements of tumor size, grade of invasion, immunochemistry, and in situ hybridization).

6.3.5. RESULTS

[0340] Results for various compounds obtained from the above-described *in vivo* assays are set forth at Table 5, below:

TABLE 5

<i>In Vivo</i> Data	
COMPOUND (Example)	EpH4-VEGF %inhibition @ mg/kg
27	56% @ 75
	50% @ 75
	63% @ 50
22	42% @ 75
	--
	42% @ 50/50
4942	46% @ 50
	47% @ 25
12	50% @ 25
	--
	57% @ 37.5/37.5
14	45% @ 50
	--
	65% @ 50
15	47% @ 50
	--
	65% @ 50


[0341] The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, and any clones, DNA or amino acid sequences which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

[0342] All references cited herein are hereby incorporated by reference in their entirety.

EP 0 934 931 A2

Claims

1. A compound of the formula



and pharmaceutically acceptable salts thereof, wherein:

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

R₃', R₅', and R₆' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

n is 0-3;

x is BR, Cl, F or I;

R is H, alkyl or aryl; and


R' is H, alkyl or aryl

2. The compound of claim 1 wherein:

R₃' is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl; and

R₅' is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl.

3. A compound of the formula:



and pharmaceutically acceptable salts thereof, wherein:

EP 0 934 931 A2

R_1 is H or alkyl;

R_2 is O or S;

R_3 is hydrogen;

R_4 , R_5 , R_6 and R_7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

R_2' , R_3' , R_5' , and R_6' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

n is 0-3;

R is H, alkyl or aryl;

R' is H, alkyl or aryl; and

R_a and R_b are each independently selected from the group consisting of H, alkyl and $C(O)R$, or $NRaRb$ taken together are a heterocyclic ring of from 3 to 8 atoms optionally substituted at one or more positions with hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$ or $CONRR'$;

with the provisos that;

(i) when R_a and R_b are both H, methyl, or ethyl, at least one of R_4 , R_5 , R_6 , R_7 , R_3' or R_5' must be other than hydrogen; and


(ii) when R_1 is methyl and one of R_a and R_b is methyl and the other is isooctyl, at least one of R_4 , R_5 , R_6 , R_7 , R_3' or R_5' must be other than hydrogen.

4. The compound of claim 3 wherein:

R_3' is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR , where R is H, alkyl or aryl; and

R_5' is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR , where R is H, alkyl or aryl.

5. A pharmaceutical composition comprising a compound of the formula:



or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier or excipient, wherein:

R_1 is H or alkyl;

R_2 is O or S;

R_3 is hydrogen;

R_4 , R_5 , R_6 , and R_7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

R_2' , R_3' , R_5' , and R_6' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

R_a and R_b are each independently selected from the group consisting of H, alkyl and $C(O)R$, or $NRaRb$ taken

EP 0 934 931 A2

together are a heterocyclic ring of from 3 to 8 atoms optionally substituted at one or more positions with hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R or CONRR';

n is 0-3;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl;


with the proviso that when the pharmaceutically acceptable carrier or excipient is selected from the group consisting of anise oil, carboxyethylcellulose and peanut oil, the compound is not 3-(4-dimethylaminobenzylidene)-2-indolinone.

6. The pharmaceutical composition of claim 5 wherein:

R₃' is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl; and

R₅' is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl.

7. A compound of the formula:



and pharmaceutically acceptable salts thereof, wherein:

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

R₃', R₄', R₅', and R₆' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

n is 0-3;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl.


8. The compound of claim 7 wherein:

R₃' is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl; and

R₅' is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR, where R is H, alkyl or aryl.

9. A compound of the formula:

EP 0 934 931 A2



and pharmaceutically acceptable salts thereof, wherein:

R_1 is H or alkyl;

R_2 is O or S;

R_3 is hydrogen;

R_4 , R_5 , R_6 , and R_7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

R_2' , R_3' , R_5' , and R_6' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

n is 0-3;

Z is Br, Cl, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, or tert-butyl;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl.

10. The compound of claim 9 wherein:

R_3' is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR , where R is H, alkyl or aryl; and


R_5' is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl and OR , where R is H, alkyl or aryl.

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound according to Claim 1, 2, 7, 8, 9 or 10.

12. Use of a compound of Claim 1 for the manufacture of a pharmaceutical composition for treating diseases related to unregulated tyrosine kinase signal transduction, said compound being selected from the group consisting of:

(i) a compound of the formula:

EP 0 934 931 A2



and pharmaceutically acceptable salts thereof, wherein:

R_1 is H or alkyl;

R_2 is O or S;

R_3 is hydrogen;

R_4 , R_5 , R_6 , and R_7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

R_3' , R_5' , and R_6' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;


n is 0-3;

X is Br, Cl, F or I;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl;

(ii) a compound of the formula:



and pharmaceutically acceptable salts thereof, wherein:

R_1 is H or alkyl;

R_2 is O or S;

R_3 is hydrogen;

R_4 , R_5 , R_6 , and R_7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

R_2' , R_3' , R_5' , and R_6' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

n is 0-3;


EP 0 934 931 A2

R is H, alkyl or aryl;

R' is H, alkyl or aryl; and

Ra and Rb are each independently selected from the group consisting of H, alkyl and C(O)R, or NRaRb taken together are a heterocyclic ring of from 3 to 8 atoms optionally substituted at one or more positions with hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

(iii) a compound of the formula:



and pharmaceutically acceptable salts thereof, wherein:

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';


R₃', R₄', R₅', and R₆' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

n is 0-3;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl; and

(iv) a compound of the formula:



and pharmaceutically acceptable salts thereof, wherein:

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy,

EP 0 934 931 A2

aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

R₂', R₃', R₅', and R₆' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

n is 0-3;

Z is Br, Cl, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, or tert-butyl;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl.

13. The use of claim 12 wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

14. The use of claim 13 wherein the blood vessel proliferative disorder is selected from the group consisting of arthritis and restenosis.


15. The use of claim 13 wherein the fibrotic disorder is selected from the group consisting of hepatic cirrhosis and atherosclerosis.

16. The use of claim 13 wherein the mesangial cell proliferative disorder is selected from the group consisting of glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection and glomerulopathies.

17. The use of claim 13 wherein the metabolic disorder is selected from the group consisting of psoriasis, diabetes mellitus, wound healing, inflammation and neurodegenerative diseases.

18. Use of a compound of Claim 1 for the manufacture of a pharmaceutical composition for regulating tyrosine kinase signal transduction, said compound being selected from the group consisting of:

(i) a compound of the formula:



and pharmaceutically acceptable salts thereof, wherein:

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

R₃', R₅', and R₆' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

n is 0-3;


X is Br, Cl, F or I;

EP 0 934 931 A2

R is H, alkyl or aryl; and

R' is H, alkyl or aryl;

(ii) a compound of the formula:



and pharmaceutically acceptable salts thereof, wherein:

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

R₄, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

R₂', R₃', R₅', and R₆' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';


n is 0-3;

R is H, alkyl or aryl;

R' is H, alkyl or aryl; and

Ra and Rb are each independently selected from the group consisting of H, alkyl and C(O)R, or NRaRb taken together are a heterocyclic ring of from 3 to 8 atoms optionally substituted at one or more positions with hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R, and CONRR';

(iii) a compound of the formula:



and pharmaceutically acceptable salts thereof, wherein:

R₁ is H or alkyl;

R₂ is O or S;

R₃ is hydrogen;

EP 0 934 931 A2

R_4 , R_5 , R_6 , and R_7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;


R_3' , R_4' , R_5' and R_6' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

n is 0-3;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl; and

(iv) a compound of the formula:



and pharmaceutically acceptable salts thereof, wherein:

R_1 is H or alkyl;

R_2 is O or S;

R_3 is hydrogen;

R_4 , R_5 , R_6 , and R_7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

R_2' , R_3' , R_5' , and R_6' are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$;

n is 0-3;

z is Br, Cl, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, or tert-butyl;

R is H, alkyl or aryl; and

R' is H, alkyl or aryl.